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Phosphoinositides are membrane phospholipids involved in a wide variety of processes
across the tree of life. In eukaryotic cells they function though their role as integral
membrane components, anchors for proteins, membrane identity markers, and
signaling molecules. Phosphoinositides are regulated through the phosphorylation and
dephosphorylation of the inositol head-group at the 3rd, 4th, and 5th positions, creating a
complex and very dynamic interconversion network. They can also be hydrolyzed into
an inositide head-group and diacylglycerol which are in turn signaling molecules. The
wide variety of functions, and redundancy in their synthesis pathways, makes the in-vivo
study of phosphoinositides complex since any experimental alterations can have
undesired effects throughout the cell. In this work I engineered the metabolic network
required to synthesize the most abundant eukaryotic phosphoinositides in the
bacterium Escherichia coli, which normally lacks any of these phospholipids. This
engineered bacterium is a new tool for the in-vivo study of cell biology models that
involve phosphoinositides, allowing for a precise control of the system and avoiding any
undesired interactions. To achieve this I built and optimized the expression of the
required enzymes into a single plasmid such that it can be used in any strain of E. coli.

My system can produce phosphatidyl inositol, phosphatidyl inositol (4) phosphate
(PI4P), and phosphatidyl inositol (4,5) diphosphate (PIP2), and is easily controlled trough
the addition of inositol to the growth media of the bacterium. As an example application
of my system, I use it to confirm the role of PIP2 binding in the non-conventional protein
export of human basic fibroblast growth factor (FGF2).
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1. Introduction

1.1.

An evolutionary outlook

As the main components of all cellular membranes, phospholipids are essential
components of all living organisms. Their basic structure consists of a hydrophobic lipid
component, two fatty acid tails, and a hydrophilic head which includes a phosphate
group, hence the name phospholipid. The head-group can be modified further with the
addition of other chemical moieties. Their amphipathic character is essential for the
formation of biological membranes because their hydrophobic tails can align towards
the inside of a bilayer, leaving the hydrophilic head towards the exterior. These
membranes create the semipermeable barrier that is essential to separate the interior
of cells from the environment, but also to separate the different organelles and vesicles
from the rest of the cytoplasm in eukaryotes.

Phosphoinositides are a class of phospholipids that have a 6 carbon-ring myo-inositol
(commonly referred to simply as inositol) head. This head-group is linked via a
phosphate to a cytidine diphosphate diacylglycerol (CDP-DAG) in Bacteria and Eukarya,
or to a CDP-archaeol in Archaea 1, and it presents a hydrogen and a hydroxyl in each of
the other 5 carbons. The carbon linked to the phosphate is carbon 1 in the myo-inositol
ring. These hydroxyls can be substituted by phosphate groups in positions 3, 4, and 5, in
any combination, creating a code that can be used by cells to differentiate among
membranes or sections of them2. Figure 1 shows a schematic representation of all
1

phosphoinositide variants and their known interconversion pathways in mammalian
cells. Phosphoinositides are present in all eukaryotes, most archaea, and some groups of
bacteria3. While the actual lipids are different in Bacteria and Archaea due to the
different linkers of each domain (ether linked in Archaea and Ester linked in Bacteria and
Eukarya), their synthesis is thought to have a common origin giving the similarity in their
biosynthetic pathways4.

Bacteria and Eukarya phosphoinositides are the same in terms of their overall structure,
with differences only in the length and saturation of the lipid tails, but their biosynthetic
pathways differ. In Eukarya the first molecule to be synthesized is phosphatidyl inositol
(PI), the only phosphoinositide that is un-phosphorylated. In Bacteria, as well as
Archaea, PI is not the first molecule to be synthesized; in the prokaryotes a
phosphorylated version is the first phosphoinositide to be synthesized, starting from
CDP-DAG in Bacteria, or CDP-archaeol in Archaea, and adding a phosphorylated myoinositol to create a phosphatidylinositol phosphate (PIP) in Bacteria or an
archaetidylinositol phosphate in Archaea. This PIP or archaetidylinositol phosphate is
then dephosphorylated to synthesize PI or archaetidylinositol. The PI-synthase (PIS) and
PIP-synthase enzymes for this first step in the biosynthetic pathway can only use their
specific substrates but are closely related evolutionarily in all three domains of life
despite this difference3.

2

Figure 1. Phosphoinositide chemical structure and interconversion pathways
The pathways shown are present in mammalian cells and represent a eukaryotic
generalization although there is variation between the major groups of eukaryotes.
Bacteria and Archaea have much simplified pathways involving only PI and
monophosphorylated phosphoinositides or no phosphoinositides at all. Only the
hydrolysis pathway of PIP2 into diacylglycerol (DAG) and inositol trisphosphate (IP 3) is
shown, since this is the best understood, but hydrolysis of phosphoinositide releasing
DAG and the corresponding inositide occurs for other phosphoinositides (see text).
Figure adapted from the works of Shah and coworkers 5 and Viaud and coworkers6.
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There is little known about prokaryotic phosphoinositides and their functions remain
poorly described, especially since until recently it was thought that it was an uncommon
occurrence in bacteria3. It is however assumed, given their presence in all eukaryotes,
that phosphoinositides were present in the last common eukaryotic ancestor and it has
been proposed that eukaryotes acquired their phosphoinositides from Archaea 7.

Phosphoinositide functions vary widely across the domains of life. The best understood
functions encompass being integral membrane phospholipids8, membrane anchors for
proteins covalently bound to them9, and anchor sites for proteins with domains specific
for their recognition2. They can also act as signaling molecules directly 10, or through the
products of their hydrolysis into DAG and inositides (the head-group)11. Inositides can
also act as compatible solutes12, as cofactors for several processes in the nucleus
involving both RNA and DNA regulation13,14, and as protein modification moieties15.

In Archaea phosphoinositides have functions as integral membrane components 8 and
inositides (just the head-group without a lipid tail) are thermo-protective solutes for
some hyperthermophilic Archaea12. In Bacteria phosphoinositides have been associated
mostly with the Actinobacteria16, which includes a large number of environmental
bacteria but also the Mycobacterium genus and Corynebacterium diphtheria, the
etiological agent causing diphtheria, which use inositides (lacking the lipid tails) as an
intracellular redox-buffer17 and as intermediates in the production of antibiotics in some
environmental actinomycetes18. Recently it was shown that phosphoinositides are
4

present in a significantly larger proportion of bacteria than previously thought but their
function in these other bacteria remains mostly unexplored 3. Photosynthesizing
cyanobacteria and α-proteobacteria have phosphoinositides so, as expected being their
descendants, chloroplast have and synthesize PI19 but its function remains poorly
characterized7. Mitochondria have a small phosphoinositide component they do not
synthesize and presumably get through their contact with the endoplasmic reticulum.
There are no known functions of mitochondrial phosphoinositides but there is an
observation that aged mitochondria can recover some of their functionality with the
addition of PI20.

Since all eukaryotes have phosphoinositides in their membranes, their presence is
considered to be an ancestral character of the group derived from an archaeal origin,
and it is in eukaryotes that their functions are more diverse 21. Phosphoinositides are
used as protein anchors in the form of glycophosphoinositides (GPI) using a complex
protein machinery for their synthesis in the ER 9. Inositol polyphosphates (the non-lipidbound version of the head-group) are used as osmoregulators by some eukaryotes just
as in some prokaryotes22.

PI is synthesized at the endoplasmic reticulum (ER) by a PI-synthase (PIS) and its
concentration is at the highest in this organelle 23. As mentioned earlier, this PIS is closely
related to that of prokaryotes, but it synthesizes PI, in contrast to PIP, in prokaryotes3.
From PI synthesized in the ER, all other forms of phosphoinositides are formed by the
5

phosphorylation or dephosphorylation of the 3, 4 and 5 positions, giving seven possible
phosphorylated variants. These variants can be localized in different membranes and
used as a code for membrane identity, a use that is considered a eukaryotic innovation.
The use of inositide-phosphate derivatives, missing lipid tails, gives even a larger
number of possibilities as a code since they can also be phosphorylated at the 2nd and
6th position. Using of both phosphoinositides and their inositide derivatives in signaling
is considered the most evolutionarily novel adaptation of inositide functionality21.

In eukaryotes, the basic biosynthetic pathway of phosphoinositides starts from the ER,
being rich in PI, with the next step in their biosynthesis being the phosphorylation to
create phosphatidylinositol-4-phosphate (PI4P) in the Golgi apparatus, and especially
the trans-Golgi system. In this way, ER and Golgi apparatus already have a characteristic
membrane phospholipid composition characterized by PI and PI4P respectively. Some of
this PI4P is carried to the plasma membrane where it is phosphorylated again in its 5 th
position to create phosphatidylinositol-4,5-diphosphate (PI(4,5)P2 or simply PIP2), which
is characteristic of this membrane21. However, there are variations that make the
system more complex. There is evidence, for example, of PI4P synthesis also at the
plasma membrane and nucleus24, but conceptually the ER-Golgi-Plasma membrane
respectively matching PI-PI4P-PIP2 in their localization and synthesis is a valid
simplification. Through mass spectrometry it was measured that PI constituted 5-10% of
the total phospholipids of a mammalian cell while PI4P and PIP2 represent only 0.51%25. Those three phosphoinositides, PI, PI4P and PIP2 represent the majority of the
6

cells phosphoinositides, with PI being the bulk of them and PI4P and PIP2 each
comprising about 5% with all others being a very small fraction of the phosphoinositides
in a “resting mammalian cell”26. This is not by any means static, as an example PI(3,5)P2
increases twenty fold upon osmotic stress in yeast 27.

Not surprisingly, the phosphoinositide code eukaryotes develop as a membrane identity
system is an essential cellular function since different phosphorylations mark different
membranes2. The phosphoinositides are always facing the cytoplasmic side of the
membranes 28. The only characterized mechanism to flip them across the membrane is
that needed for the use of GPI anchors for some proteins. This occurs in the ER which
involves a PI without additional phosphorylation 9, although PI3P has been found in the
lumen of Plasmodium falciparum’s ER and been associated with secretion29. This
perhaps reflects an adaptation to be exposed to the cytoplasm of the host upon vesicle
fusion with the plasma membrane of the parasite. There is also an observation of PI3P
present in the outside membranes of some mammalian and plant cells but this remains
largely unexplored30.

7

1.2.

Synthesis, distribution, regulation and function of eukaryotic
phosphoinositides

Despite the relative low abundance of phosphoinositides, they perform a wide variety of
essential functions. Phosphoinositides function as signaling intermediates31 and in
overall membrane biology32, including cell division33, cortical actin organization34, and
membrane curvature control, either directly or through their protein interactors35.
Additional roles for phosphoinositides have been reported in the nucleus in chromatin
maintenance36. This functionality is given by all 8 possible combinations of
phosphorylation at the 3rd, 4th or 5th position of PI, creating the phosphoinositide code.
Figure 2 shows a schematic representation of phosphoinositide location and abundance
in a mammalian cell. Given the tight regulation of the phosphoinositides both in
localization and phosphorylation state I will discuss the synthesis, distribution and
functions of them simultaneously.

Regulation of phosphoinositide abundance, and therefore their functions, is very
complex. At the basic level it represents a complex balance between synthesis and
degradation, where it’s important to consider that for the most part this means another
type of phosphoinositide is formed either by addition or removal of a phosphate. The
synthesis might be under more stringent control than the catalysis since the
phosphoinositide phosphatases tend to be more promiscuous than phosphoinositide
kinases regarding their substrates37.
8

Figure 2. Schematic representation of phosphoinositide location and abundance in a
mammalian cell
Figure adapted from the works of Shah and coworkers 38 and Viaud and coworkers6.

9

The higher substrate promiscuity of the phosphatases does not mean in any way that
they are not regulated, in fact tyrosine phosphorylation is a well characterized form of
regulation for the phosphatases and it’s been proposed that serine/threonine
phosphorylation is relevant as well 39. The exception for this phosphoinositide
phosphorylation/dephosphorylation balance is degradation via separation of the headgroup from the fatty acids by phosphoinositide specific phospholipase C (PLC), creating
diacylglycerol (DAG) and the inositol phosphate moiety corresponding to the
phosphoinositide of origin40 compounds that are in turn major signaling molecules11.

Regulation extends beyond synthesis and degradation with sequestration of
phosphoinositides representing an alternative form of regulation 41 and the segregation
of phosphoinositides across organelles42 or sections of the same membrane being
another important factor. It has been shown for example that different pools of the
same phosphoinositide being present in the same membrane but linked to different
kinase isoforms are important in aspects of immune cell calcium regulation and
signaling43 as well as vesicle and overall organelle trafficking 44. Perhaps the best studied
system is the sequestration of PIP2 by proteins to release these stored pools upon Ca+2
binding45. But as in most phospholipid studies the validity of results indicating any sort
of “rafts” or segmentation between membranes has been questioned functionally, in
this case by showing two proteins with very distinct localizations on the membrane use
the same PIP2 pool46. This picture is much more complex since it is now clear that some
of the enzymes involved in phosphoinositide synthesis have preferences for certain fatty
10

acid moieties creating another way to regulate the system 47 48. This type of difference is
functionally relevant as shown with the differences between regular and stress induced
phosphoinositide pools in Arabidopsis49, where it’s also been shown that differences in
the fatty acid tails propagate from the synthesis of PI to different PIPs selectively50.
Whether this is an explanation that applies for all observed differences between pools
of the “same” phosphoinositide in cells is still an open question although it wouldn’t be
a surprising observation.

The length of the lipid tails varies significantly between yeast, mammals and plants.
Yeast phosphoinositides possess fatty acid tails in the range of 26 to 36 C atoms per DAG
molecule (which includes two fatty acids) and a maximum of 2 double bonds with
several moieties being completely saturated. Mammals have between 34 and 40 C
atoms per DAG, up to 6 double bonds, and there is always at least one double bond
between the 2 lipid tails25. Plants showing a similar composition to that of mammals
with a slightly larger range, including molecules with only 32 C atoms but the same
range of double bonds49. Additionally there is evidence for ether linked inositol
phospholipids in Dictyostelium, although their function seems to remain the same as in
mammals51. This suggests that the lipid moieties might not be as relevant for the
function of phosphoinositides, supporting the role of protein domains that bind to their
head-groups as the major effectors of phosphoinositides. Also, since the lipid
composition of membranes is controlled as a way to regulate fluidity 52, the changes in
the fatty acid tails of phosphoinositides could just reflect the overall status of the cells
11

phospholipids. The evidence for some differences between different phosphoinositides
and other lipids during stress in Arabidopsis49 suggest this might not always be the case.
Overall, the extent over which phosphoinositide fatty acids play a role in their functions
beyond affecting their membrane mobility and localization is still an open question.

As mentioned earlier, PI is synthesized at the ER from CDP-diacylglycerol, a common
precursor for other lipids, by PIS which is a membrane bound protein found in the
tubular ER23. PI can then be transferred to other membranes by proteins specialized on
its transfer 53 and potentially by the normal vesicular transport between ER and Golgi 54.
The transference of PI is however not fully characterized, and given its essential role
both as a structural phospholipid and as the precursor of PIPs, which are quickly
replenished upon their depletion on signaling activation, a more complex mechanism
has been proposed. This mechanism involves a special ER derived organelle that has
contact with numerous other membranes and acts independently of the main ER bound
PIS, with the different population of PIS having different activities. The experiments that
characterized this organelle did not however provide a clear picture as to how it
interacts with the ER showing only that it is separate and not continuous with other
membranes during the experiments55. However, no further support for this organelle
has been reported. The function of PI transfer proteins is also now thought to be more
complex than initially conceived. The transfer proteins have recently been proposed to
have a role in presenting PI to the PI-kinases56. There are no protein motifs with specific
binding to PI and its function is therefore assumed to be mostly structural or as a
12

precursor of PIPs but, while these are definitively important roles for it, this might
reflect more a lack of tools for its study than the reality in cells 55.

PI can then be phosphorylated at its 3rd, 4th, or 5th positions generating PIP, but of these,
PI4P is the most abundant form26. There are 4 different kinds of PI-4 kinases in
mammals and 3 in yeast. These show different cellular localization and act on the
maintenance of different pools of PI4P, although several occur simultaneously at the
plasma membrane or Golgi57. PI4-kinases have also been shown to occur at secretory
vesicles58 and are known to shuffle between the Golgi and nucleus being essential for
viability of yeast in both locations59. Synthesis of PI4P is a complex process that is linked
to the overall maintenance of ER-Golgi lipid transfer where the gradient in PI between
the membranes is used to transfer other lipids; the conversion of PI to PI4P in the Golgi
maintains this gradient60. PI4P is also an important component of the plasma membrane
with many proteins showing erroneous localization upon selectively depleting this pool
of PI4P61. The function of PI4P is then shown to be not only as a precursor of PIP2, for
which different pools have different relevance, but also directly as a scaffold for the
binding of proteins to the appropriate membranes. This interaction has been shown to
be essential for Golgi vesicle transport62. It is common for proteins binding PIPs to
present an interaction as a combination of specific and non-specific electrostatic
interactions63 providing a marker for different membranes. This “membrane code” is
not exclusively phospholipid based and in many cases an interaction with both PI4P and
one or more proteins is required64, a situation that is common to all phosphoinositides.
13

There is also evidence of the importance of PI4P in a counter-transport of phospholipids
between ER and plasma membrane, in this case helping to enrich phosphatidylserine in
the plasma membrane using the PI4P gradient as the driver65, 66. This PI4P is in turn
dephosphorylated to PI in the ER in a manner that allows for the regulation system
based on PI4P abundance67. PI4P dephosphorylation into PI is catalyzed by
phosphatases with the SAC1 domain 68.

The next major step in PIPs synthesis is the phosphorylation of PI4P in its 5 th position to
make PIP2. While PI kinases share some homology with protein kinases, the PI4P-5kinases show no homology to any other kinases and constitute a separate family of
kinases24. Their active site does however have structural similarity to protein kinases69.
There are two types of PIP kinases known to generate PIP2, type I and II. Since type II
have a preference for PI5P as their substrate70, the bulk of PIP2 is synthesized by PI4P-5kinases type I at the plasma membrane directly from PI4P synthesized there24. However,
there is evidence supporting an important role of Golgi PI4P as a precursor of PIP271. If
the pool of PI4P available as a precursor is disrupted the PIP2 synthesis occurs in other
cellular compartments from other PI4P pools and is not localized correctly to the plasma
membrane61. From this plasma membrane PIP2 is where most other PIPs, which are
generally short lived, are synthesized either directly or through PI(3,4,5)P3 (PIP3) as an
intermediate. The head-group of PIP2 can also be cleaved by phospholipase C releasing
inositol triphosphate (IP3) and DAG as a signaling molecules72, 73.

14

PIP2 is directly involved in a very diverse array of functions at the membrane that
include structural effects on membrane curvature35, cortical actin organization34, acting
ring binding at the cleavage furrow during cell division 74 and overall actin regulation at
the membrane75, endocytosis76, vesicle recruitment and docking77, exocytosis78, ion
channel gating79, basement membrane polarization maintenance 80, ER-plasma
membrane interactions81, regulation of dopamine transporter activity82, regulation of
other lipids through ceramide kinase localization83, membrane potential sensing
through changes in its localization 84, regulation of the phospholipase D family (PLDs)
through both localization and activation of the enzymes 85, localization of signaling
proteins and complexes to the plasma membrane 86, regulation of mitogen-activated
protein kinase (MAPK) signaling though localization of scaffold proteins87. Thus, many of
the functions that involve plasma membrane identity are in one way or another
dependent on PIP2.

In the functions already mentioned activity is mainly dominated by phosphoinositides
acting as a platform for the recruitment of proteins, however, functions of
phosphoinositides much more complex. Interconversion between phosphoinositides is
perhaps the rule when it comes to their diverse functions. As an example PIP2 is
excluded from cilia and hypothesized to be dephosphorylated into PI4P as a way to
maintain the transition zone and compartmentalization of cilia 88 and it’s been shown
that this conversion is essential for ciliogenesis89.

15

The major function of phosphoinositide turnover might however be in signaling
pathways. As an example, the cold sensitive TRPM8 Ca2+ channels are activated by a
combination of PIP2 and cold or menthol, and in turn the Ca2+ input activates Ca2+
sensitive phospholipase C which degrades PIP2 and releases IP3 and DAG providing both
a negative feedback and a signaling event90. In metazoans DAG is active in the
membrane itself as an activator of ion channels, protein kinase D, members of the
protein kinase C family, RasGRP1 (which is involved in the Ras/MEK/ERK signaling
pathway), and neurotransmitter secretion91. IP3 is soluble and acts on specific receptors
in the ER leading to Ca2+ release92. In plants DAG is phosphorylated before it has a
signaling function and it is also phosphorylated derivatives of IP 3 that are signaling
effectors93. Currently it is considered that direct signaling by DAG and IP3 from PIP2
through phospholipase C is a metazoan innovation 7.

PIP2 is therefore considered a signaling molecule in itself. Not only is it the precursor of
major signaling pathways, but by changing the availability of PIP2 the recruitment of
proteins complexes to the plasma membrane and the activation of ion channels and
receptors can be controlled. This emphasizes the still unsolved question as to how are
so many functions and the possible crosstalk between them regulated 94. The function of
PIP2 as the major precursor of PIP3 adds an extra level of complexity to the system as
does the positive feedback loop that PIP2 can have on the activation of PIP-kinases95.

16

Although the other phosphoinositides show very low abundance in the cells the
diversity and relevance of functions they perform make them essential cell components.
Perhaps the most studied one is PIP3, which is a major signaling hub involved in a
variety of functions related to cell movement such as wound healing, directional
movement of cells, neuronal patterning and embryogenesis, but also in the immune
response96. This PIP3 signaling pathway seems to be metazoan innovation93, in it PIP2 is
phosphorylated by a class I PI3-kinase upon activation by G-protein-coupled receptors
(GPCRs) and/or receptor tyrosine kinases generating PIP3. As expected from the
involvement in GPCR signaling the PI3-kinases are regulated through binding to other
proteins of which G-proteins, and GTPases in the Rho and Ras families are common
interactors97. Given the importance of these signaling pathways and the low basal
abundance of PIP3 in cells it’s not surprising its half-life is quite short, of less than 5
seconds98. PIP3 acts by the very fast recruitment of proteins with binding domains
specific to it, of which the serine/threonine protein kinase Akt (known as well as protein
kinase B, PKB)99, and the phosphoinositide-dependent kinase 1 (PDK1)100 are the most
studied. Both kinases are involved in a variety of essential signaling networks related to
cellular migration, proliferation and metabolism. The signaling pathways involving PIP3
are grouped as PI3K signaling pathways, named for the class I PI3-kinase that
synthesizes it. PIP3 can be degraded through two pathways. It can be dephosphorylated
at its 3rd position to generate PIP2 again, a reaction catalyzed by the phosphatase and
tensin homolog deleted on chromosome 10 (PTEN)101, or by dephosphorylation of its 5th
position by phosphatases synaptojanin or src homology 2-containing inositol
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phosphatase (SHIP) producing PI(3,4)P2 which is another of the minor
phosphoinositides102.

PI(3,4)P2 can be synthesized in two ways: by dephosphorylation of PIP3 or by
phosphorylation of PI4P in its 3rd position by a class II PI3-kinase. The roles of PI(3,4)P2
are still mostly unknown with very few protein interactors identified 103. It has been
shown to be involved in lamellipodia 104 and podosome105 formation where several of
the proteins relevant for these processes have domains that bind specifically to this
phosphoinositide. In a more detailed experimental setup it has been shown to be used
as a negative regulator of PI3k signaling through its interactions with tandem pleckstrin
homology-domain-containing protein 1 and 2 (TAPP1 and TAPP2) in the control of
insulin signaling with deregulation occurring upon genetic ablation of the interaction
with TAPP1 and TAPP2106. The best studied role of PI(3,4)P2 is in clathrin mediated
endocytosis, where it’s been shown to control the enrichment of late stage endosome
proteins, and is absence causes the endosome to become an elongated tubular
structure before fission107. This is mediated by phosphorylation of PI4P in its 3 rd position,
and this PI4P is also been shown to be the product of PIP2 dephosphorylation 108
providing a precise mechanism for the control of clathrin mediated endocytosis by
phosphoinositide transition and the different proteins they recruit 109. PI(3,4)P2 has also
been shown to be involved in clathrin-independent endocytosis activated by receptor
activation of the PIP3 pathway110. It is unclear whether PI(3,4)P2 really has just these
functions or if its low abundance and fast dynamics have precluded the discovery of
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more. It nonetheless has been proposed as an important molecule downstream of the
PI3K signaling pathway and hypothesized to have more functions, with the current lack
of understanding being a product of lack of interest in the research community 103. Given
the wide variety of functions involving PIP3 and the known importance of endocytosis
(where PI(3,4)P2 role is well characterized) for receptor signaling and recycling it would
not be surprising for PI(3,4)P2 to have a central role in PI3K signaling as proposed.

The other three minor phosphoinositides PI3P, PI5P and PI(3,5)P2 have all low
abundance but are still very important in the cell. It’s been proposed that as a group
they allow for the regulation of some types of vesicular traffic and cytoskeletal
processes6. PI3P is generated by the phosphorylation of PI in its 3rd position by a PI3kinase or by the dephosphorylation of PI(3,4)P2 or PI(3,5)P2 in their 4th and 5th position
respectively. There are 3 classes of PI3-kinases all of which phosphorylate the 3rd
position in phosphoinositides but of which class I and class II show substrate promiscuity
in vitro, although respectively preferring PIP2 and PI as their substrates. Class III PI3kinases do show specificity only for PI as a substrate111. The generation of PI3P by
synthesis from PI seems to be common to all eukaryotes while its synthesis by
dephosphorylation of PIPs might be exclusively metazoan112. As with all
phosphoinositides PI3P can be degraded through lipases, and by being
dephosphorylated or phosphorylated. Lipases represent the main pathway for its
degradation in yeast and mammals, a process that occurs in the endosomal pathway 113.
It is precisely the endosomal pathway that presents the best known function of PI3P
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where it serves as an anchor for the endosomal sorting complex required for transport
(ESCRT) machinery, in particular for ESCRT-0 and ESCRT-II 112, although in vitro the
interaction of the ESCRT complex with vesicles proceeds in the absence of
phosphoinositides at a lower rate114. PI3P is considered to be important for endosome
recycling where sorting nexin (SNX) protein 1 has been shown to bind PI3P and PI(3,5)P2.
There is evidence for the involvement of PI3P in regulated exocytosis in neurons115 but
the mechanism is still unknown112. PI3P has also been shown to be essential for
autophagy where its synthesis at the ER helps to segregate the membrane that will
become separated to form the autophagosome116 and there is some more detailed
mechanistic understanding of the process in yeast, although it is known that the protein
binding domains that interact with PI3P in autophagy also bind to PI(3,5)P2117. Finally
there is some mechanistic evidence for PI3P involvement in cytokinesis118 and signaling
although this role might be indirect due to the role it has in endosome sorting 112.

PI(3,5)P2 is a poorly studied phosphoinositide given its low abundance and the lack of
tools for its precise localization. It can be produced by the phosphorylation of PI3P in its
5th position or of PI5P in its 3rd position with the first pathway dominating its
production6. Theoretically it could also be synthesized through dephosphorylation of
PIP3 in its 5th position but there seems to be no evidence for this pathway. The PAS
(PIKfyve/ArPIKfyve/Sac3) protein complex localizes to the endosomes and contains both
the kinase PIKfyve that phosphorylates the 5th position of PI3P and the phosphatase
Sac3 that dephosphorylate it back to PI3P119. PI(3,5)P2 is essential for vesicle recycling
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from vacuoles and lysosomes120 and endosome to trans Golgi network recycling121.
Given the promiscuity in some of the protein binding domains that recognize both PI3P
and PI(3,5)P2117, and their closely related synthesis and localization 119, it would not be
surprising if they share functions or some of their ascribed functions are actually
performed by the other phosphoinositide, with both possibilities likely happening. It is
nonetheless clear that both PI3P and PI(3,5)P2 are important factors for vesicle sorting in
cells6.

Finally PI5P was the last phosphoinositide to be discovered and the one with the lowest
abundance in cells although, as is usual for phosphoinositides, variability exists122. It is
localized to the plasma membrane, ER, Golgi apparatus, endosomes, and nucleus123. It
can be synthesized by phosphorylating PI, or dephosphorylating PI(3,5)P2, or PIP2, but
its degradation seems to be coupled mostly to its phosphorylation leading to PIP2
synthesis6. Most of its functions remain poorly studied but it’s been associated with cell
motility124, glucose metabolism upon insulin activation in adipocytes125, negative
feedback loops in T-cell signaling126, and in autophagosome biogenesis in a way
independent of PI3P but which shares some of the effectors 127. The best characterized
functions of PI5P are however in the nucleus where it has been shown to bind ING2, (a
candidate tumor suppressor) in-vivo, and regulate its ability to activate p53 and
apoptosis128 as well as have a role in chromatin structure 129.
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Functions of phosphoinositides in the nucleus are not exclusive of PI5P and involve at
least PI, PI5P, PI4P and PIP2 in the most characterized models. PI3P and PIP3 have also
been detected but their functions remain obscure38. There are several lines of evidence
for Ca2+ signaling in the nucleus through phospholipase C hydrolysis of PIP2 into IP 3 and
DAG as occurs in the cytoplasm130. In this case with the Ca2+being released from the ER
and nuclear envelope131. This system has been associated with cell cycle progression
and differentiation132. Also, another function that seems to be shared with the
cytoplasm is the binding of PIP2 to actin or other cytoskeletal related proteins inside the
nucleus133. The most surprising observation is that the nuclear phosphoinositides aren’t
all in the nuclear envelope membrane, but in the nucleoplasm itself with the key initial
observation being that of a significant fraction of PIP2 (35%) remaining in nuclear
preparations that had been stripped of their membranes by treatment with
detergent134. It was shown that PIP2 co-localizes with PIPKIα, a PI4P-5-kinase to nuclear
speckles135 which are dynamic structures involved in RNA processing and maturation 136.
The essential role of PI-4-kinases in the nucleus of yeast59 as well as their known
localization to the nucleus in mammalian cells137, make the PI-PI4P-PI5P-PIP2 axis clearly
relevant in the nucleus where it’s been implicated into mRNA processing and export 138.
As mentioned before, PI5P has a more characterized role in P53 dependent apoptosis128.
PI5P has also been shown to be in the chromatin fraction and its amount increases upon
UV damage supporting a role in chromatin structure129.
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An additional level of complexity is given by the fact that a variety of inositol
polyphosphates (just the inositol head-group lacking any lipid tails) can be generated
from IP3 in the nucleus and have associations with proteins involved in RNA editing 13,
RNA export139, chromatin remodeling140, telomere length141, non-homologous end
joining14, and potentially a novel type of protein modification by adding the
pyrophosphorylated bond from IP7 or IP8 to a serine that is already phosphorylated15.
But for all these functions it is unknown if inositol polyphosphates act simply as
cofactors or are actually regulated and the changes in their abundance serve as ways to
control these processes38. In the case of Trypanosoma brucei the control of the antigen
switch and regulation of telomeric expression sites, which is essential for its escape from
immune detection, is directly linked to phosphoinositides cycling including the PI4PPIP2-PIP3 axis but also PI(3,4)P2, and the soluble head groups IP3, IP4, and IP5,
reinforcing the notion of a code that is shared both by the soluble head-groups and the
phosphoinositides themselves142.

1.3.

How phosphoinositides’ functions are performed and how we study them

The very wide array of functions in which phosphoinositides have been implicated
makes a detailed description of the evidence for each of them too lengthy for the scope
of this thesis. I will instead provide an overview of the mechanistic patterns on these
functions as well as the methods useful for the study of phosphoinositides, emphasizing
particular methods or discoveries when appropriate.
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1.3.1. Phosphoinositides in membranes

Phosphoinositide functions in maintaining/altering the membrane curvature can be
direct through their inverted conical shape for the phosphorylated forms (big head
group volume relative to a small lipid tail volume) which leads to positive curvature in
membranes, but most of their known role in altering membrane seems to be mediated
through their interactions with proteins which can also modify the membrane
properties by inserting domains into it upon phosphoinositide binding 35. Given the very
high complexity of living cells and the intrinsic difficulty of controlling membrane
composition in-vivo, studies of this kind of activity are done on artificial membranes. A
good example of how this type of study is performed is provided by the work of
Rusinova and collaborators143. In it they worked by creating lipid bilayers over 1.5 mm
diameter pores and varying the lipid composition using gramicidin A channels as
reporters. The use of gramicidin A channels relies on their apparent independence on
specific lipid binding for their function, but their requirement for a bilayer compression
for their activity. This occurs because they function as dimers, one monomer on each
leaflet of the membrane, thus the probability of dimerization depends on the properties
of the membrane they reside on. As a dimer they allow the flux of monovalent cations
and water allowing electrophysiological measures to be taken. There are gramicidin A
channel variants with different lengths allowing for a more detailed control of the
system144.
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In the work of Rusinova and collaborators143 the composition of the lipid bilayers was
maintained at PIP2 levels that are physiologically relevant but changing the type of PIP2
that was used from endogenous PIP2 purified from brain, to exogenous PIP2 with short
(carbon chains 8 long all saturated) or long (carbon chains 18 long with one double
bond) fatty acid tails. The rational for this was to evaluate if there are differences
between endogenous PIP2 and the exogenous ones that are more commonly used in
research with artificial membranes. The main result of this analysis was that the
properties of the bilayer are not affected at low concentrations of phosphoinositides
while direct effects on the membrane are observable at high concentrations (>10 μM).
This conclusion is important because it highlights the potential that the enrichment of a
phosphoinositide has to alter membrane properties. It implies that when binding to
proteins in a membrane, if the proteins have a tendency to aggregate, or if they bind to
areas already rich in phosphoinositides and stabilize them, phosphoinositides can not
only alter the proteins upon binding to their specific binding sites but the properties of
the section of membrane. No clear pattern was observable when it came to the
comparison between exogenous and endogenous phosphoinositides.

The use of artificial vesicles and membranes has been instrumental for the study of
phosphoinositides. While these systems do not present the complexities of a living
membrane or cytoplasm (for example not allowing membranes with asymmetric
distribution of lipids to be used) being able to control precisely the lipid composition
allows for a wide variety of experiments. As mentioned earlier this approach has been
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useful to test the effects of PIP2 on membrane properties 143. The use of unilamellar
vesicles has allowed some very detailed studies such as the role of the ESCRT-III
Complex in membrane scission, although in these experiments the phosphoinositide
involved, PI3P, was kept constant114. The concept of lipid domains or “rafts” is also
relevant here since artificial vesicles have also been used to test hypothesis about the
distribution of phosphoinositides. Lipid rafts rich in PIP2 have been proposed as a
mechanism involved in actin dynamics at the cell cortex 145. In order to test how such
rafts could regulate the neuronal Wiskott-Aldrich Syndrome Protein (N-WASP), which
normally has a self-inhibitory mechanism until bound to PIP2, vesicles with different
concentrations of PIP2 were used showing that the affinity of N-WASP for PIP2 depends
directly on PIP2 concentration. These results provided evidence for a cooperative
binding model that involves several molecules of PIP2 thus explaining the need for a
locally high concentration of the phosphoinositide for N-WASP activity on actin
polymerization, such as in a hypothetical raft. In this study the authors went further
showing that increasing the amount of basic residues in the phosphoinositide binding
patch allowed the interaction to take place at lower PIP2 concentrations 146.
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1.3.2. Phosphoinositides and proteins

Knowledge of phosphoinositides in the realm of membranes is very limited compared to
that of their functions interacting with proteins2. This is likely the result of difficulties
studying the biophysical properties of membranes in-vivo combined with the relatively
low abundance of phosphoinositides. The interactions of phosphoinositides with
proteins are mediated through their roles as scaffolds for protein binding with varying
specificities. There are many protein domains specialized in phosphoinositide binding
including PH, ENTH, CALM or ANTH, PTB, PHD, C2, BAR, PX, PDZ, FERM, Tubby, and FYVE
domains2, 147-149 (the names of these all come from acronyms of the original proteins
they were found and have little relevance). Most of these domains are also present in
plants and yeast suggesting they have an ancestral eukaryotic origin 93. Of these the PH
domains and C2 domains are notable because they are some of the most abundant
protein families in the human proteome150 while the PHD domain seems to be
particularly common in proteins involved in chromatin maintenance and histone
interactors38. The C2 domain has been studied phylogenetically showing a very
interesting pattern in which the last universal eukaryotic ancestor is hypothesized to
have at least 6 families of C2 domains. This study also showed that the calcium
dependent membrane binding is exclusive to the protein kinase C-C2 domain family and
no other C2 domains151. Given the well characterized importance of phosphoinositide
signaling for calcium regulation 152, this calcium conditional C2 domain represents a very
useful evolutionary adaptation to provide feedback in signaling networks.
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The charge of phosphoinositides is an important factor for their interaction with protein
domains specialized in binding to them. Nuclear magnetic resonance studies have
determined that PIP2 charge is -4 at pH 7.0153, but based on vesicle mobility in a
potassium buffer at pH 7.0 its charge seems to be -3 since it can bind both a K+ and H+
ion154. It has been proposed that the H+ ion can be removed by protein interactions thus
giving PIP2 a possible charge of -3, -4 or -5 depending on its interactions. For many of
the protein domains that interact with phosphoinositides the interaction is given in a
non-specific way by this charge and other membrane properties that phosphoinositides
impart. Clusters of basic and aromatic residues are common among domains that bind
to phosphoinositides95. In an experimental set up using phosphatases targeted to the
plasma membrane it was shown that this polybasic cluster is important for protein
localization to the plasma membrane of a large proportion of the proteins that localize
to this compartment. An unexpected result of the study was however the necessity for
PIP2 and PIP3 removal suggesting that PIP3 shares the plasma membrane identity role
with PIP2155.

The binding of proteins to phosphoinositides can be very promiscuous or specific
depending on the specific domain156. It is not uncommon to find that the domain binds
the phosphoinositide with similar affinity as the isolated inositol phosphate head-group;
the PH domain from phosphor lipase C-δ (PLC-δ) for example binds both PIP2 and IP3
with high affinity157. This property has been exploited for crystallographic studies which
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are commonly performed with the proteins bound to only the head-group of the
phosphoinositide158, 159. Evidently this methodology is very useful when studying
inositides phosphates (the naturally occurring head-groups that lack lipid tails).

Specific interactions can also be more complex with the binding sites for a
phosphoinositide forming between two interacting proteins, as is the case between
phospholipase γ1 and the ion channel TRPC3, which form a PH domains that binds PIP2,
localizing the channel to the plasma membrane. This result is interesting not only
because of the potential for more complex interactions it illustrates but because it was
found through an in-silico approach to identify phosphoinositide binding partners 160. A
well characterized non-specific protein-phosphoinositide interaction is the
myristoylated alanine-rich C kinase substrate (MARCKS), which has a patch of basic
residues in an unstructured domain that allow it to bind PIPs in a non-specific manner.
This binding occurs through electrostatic interactions aided by the insertion of the
myristoyl moiety into the membrane. This interaction is regulated by the
phosphorylation of serine residues in the basic path causing cytosolic localization of the
protein161. It’s important to highlight that this is an interaction of the MARCKS
phosphoinositide binding domain with 3 molecules of PIP2 allowing it to both sequester
PIP2 more effectively and bind preferentially to areas of the membrane rich in PIP2 45.

While most of our knowledge about the interaction of protein domains and
phosphoinositides seems to indicate it is their head groups that drive the interaction,
29

the lipid tails are an important part for a few known cases. The most obvious one is that
of phosphoinositide transport proteins, which need to house the hydrophobic lipid tails
in order to transport them successfully162. This does not imply that the lipid tails play an
important part for their functions, since it is simply a requirement for their transport by
burying the hydrophobic lipid tails in a pocket in the protein and leaving the hydrophilic
head-group exposed to the cytoplasm. However this mechanism has been hypothesized
as a way in which phosphoinositides could perform functions in a way independent of
the membranes they normally are part of. The argument is that since most protein
interactions seem to work directly with the head-group, a protein that carries
phosphoinositides with the head-groups exposed could lead to successful
phosphoinositide-protein interactions. This could be a particularly useful mechanism to
explain the functions of phosphoinositides in the nucleus 138. Recently this was shown to
be the case for the human steroidogenic factor-1 ligand (SF1) binding domain (a nuclear
receptor), which can bind to both PIP2 and PIP3, hiding the lipid tail in the hormone
binding pocket (common to nuclear receptors) and exposing the head groups to the
cytoplasm. The surface that is created by this binding, and which includes the
phosphoinositide head-group, matches the binding site of a protein interactor of SF1
providing a mechanistic model for the effect of some mutations to SF1 which were
previously not understood at the structural level10. Whether variation of lipid tails in the
phosphoinositides allow for regulation of this type of process is still an open question,
but it is now clear that phosphoinositides can have functions that aren’t linked to
membranes though this “protein presenting” mechanism.
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The study of phosphoinositide binding to proteins has used the expected biochemical
assays including crystallography163, nuclear magnetic resonance164, radioactively labeled
phosphoinositides in in-vitro binding assays70, and calorimetry156. Assays specific to
phospholipids such as protein lipid overlays165, and protein binding to vesicles with
known lipid compositions have also been used 156. Protein lipid overlays are particularly
relevant because they are analogous to dot blots. In them purified lipids are blotted and
incubated with proteins which are then detected with a secondary antibody. This
provides a straight forward way to detect the binding preferences of proteins165, and
has been transformed into a system commercialized for the quantification of some
phosphoinositides and as the basis for ELISA assays for phosphoinositide quantification.

As expected, there is a wide range of affinities for protein binding to phosphoinositides
and whether in vitro measures reflect the reality in cells is still an open question 95. The
KD of PH domain from pleckstrin (which gives the name to the specialized
phosphoinositide binding PH domain as an acronym to Pleckstrin Homology) has been
measured at 30 μM through binding to vesicles166, while that of the PH domain of PLC-δ
has been measured at 2 μM through several independent techniques95, 157, 167. The
affinity and specificity of some phosphoinositide binding domains has made them a very
useful tool for the study of phosphoinositides in-vivo. By combining a phosphoinositide
binding domain and a fluorescent protein reporter a genetic reporter for
phosphoinositide location is created. This has been an instrumental tool for the in-vivo
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study of phosphoinositides allowing studies of their dynamics as well as quantification
of their abundance in some cases168. Antibody staining against phosphoinositides has
also been used but in the majority of cases antibodies are used only for
immunohistochemistry and have therefore limited utility given the very dynamic nature
of phosphoinositides169.

Phosphoinositide binding domains have also been used in more complex schemes
involving fluorescent resonant energy transfer (FRET) as a way to increase sensitivity 170
and a similar approach has been done using a split luciferase171. Overexpression of a
phosphoinositide binding domain has been used as an approach to sequester the
phosphoinositide in order to tests its importance for a specific function, such as
overexpressing the pH domain of PLC-δ to inhibit receptor mediated endocytosis172. In
the specific case of PI3P the use of a FYVE domain that dimerizes with the addition of
the rapamycin derivative, AP20187, has the advantage of allowing overexpression of the
protein without side effects. This is because it remains cytoplasmic as an inactive
monomer, avoiding any negative effects, until AP20187 is added causing the FYVE
domain dimerization and sequestration of all PI3P available 173.

Despite the widespread use of phosphoinositide binding domains for their study there
are significant caveats to their use. The most commonly mentioned problem is the
possibility that their study interferes with the normal processes in which
phosphoinositides are involved. This occurs because by binding to proteins the
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phosphoinositides are in effect sequestered, precluding the activity of any enzymes that
would act upon them or their binding of effectors6. This is well illustrated with the
measured half-life of PIP3 which was estimated to be less than 10 seconds when
measured without using phosphoinositide binding domains (in this case a PH domain)
but when measured using a PH domain it was close to 1 minute 98. The promiscuity of
the binding domains can be an important problem too, especially since our knowledge
of their binding affinities came from in vitro studies 31. The pH domain of PLC-δ is widely
used for the detection of PIP2 because of its KD of just 1.66 μM, but its KD when binding
IP3 is just 0.21 μM 157, making interpretation of results obtained with it very complex
since an increase in soluble IP3 would give the same result as a decrease in PIP2174.

However, the biggest problem for the use of phosphoinositide binding domains to study
phosphoinositides might come from the assumption that these domains only interact
with phosphoinositides and/or that different domains interact in the same way 174. As an
example, the PH domains of both Bruton’s tyrosine kinase and Cytohesin-1 bind to PIP3
and therefore bind to the plasma membrane upon activation of Jurkat cells. However
overexpression of cytohesin-1 PH domain inhibits the cell adhesion of stimulated Jurkart
cells while that of Bruton’s tyrosine kinase does not175. Since their binding and
localization is the same this observation is most likely the result of differences in their
interactions with other molecules. Different phosphoinositide binding domains have
also been shown to have different localization or even miss entirely some pools of
phosphoinositides31. This problem is not exclusive of phosphoinositide binding domains,
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the PTEN phosphatase has phosphatase activity on both phosphoinositides and
polypeptides through the same active site176, so interpretation of results from
modifications to PTEN activity, localization, or abundance is very complex.

This “problem” when interpreting experimental results illustrates an important aspect
of phosphoinositide behavior. Given that most binding domains do not show high
affinity for their preferred phosphoinositides and are promiscuous in their binding
partners174, the functions of phosphoinositides have been proposed as the result of
coincidence detection in which it is the simultaneous binding of proteins to
phosphoinositides and other proteins that allows for their functions to occur 31. In this
way the “membrane code” is not given exclusively by the phosphoinositides but by a
combination of phosphoinositides and proteins that do not necessarily interact directly
with them. Of the proteins that share this scaffolding/code function the Rab-GTPases
are particularly relevant given their importance for membrane and vesicle trafficking
across the cell177. The coincidence detection is not limited to phosphoinositides and/or
proteins, membrane properties are also employed. The best example might be that of
the sorting nexin-1 (SNX1) protein which has both a PX domain that binds to PI3P and
PI(3,5)P2, and a Bin-Amphiphysin-Rvs (BAR) domain that allows it to form dimers that
sense membrane curvature, as determined by its binding to vesicles of the same
components but different sizes. In this way both the phosphoinositide binding and the
membrane curvature allow targeting of SNX1 to the early endosome 178.
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The study of phosphoinositide location by using labeled phosphoinositide binding
domains or antibodies has been instrumental to our knowledge of their functions
despite the caveats of each method. More classical cell biology approaches have also
been used successfully. While the fine scale details are lost in these approaches the
fractionation of membranes and quantification of the phosphoinositides afterwards
gave the first suggestion for non-membrane-bound nuclear phosphoinositides as
mentioned earlier134. Radioactive labeling, using 3H labeled inositol, has also provided a
way of quantifying phosphoinositides through thin layer chromatography or high
performance liquid chromatography coupled to mass spectrometry. This approach
however is complicated because the three mono-phosphorylated and the three diphosphorylated isomers are not distinguishable by these methods 169. A chemical
modification that allows for the distinction of isomers in mass spectrometry has been
developed179 but it remains available only to specialized laboratories since it requires a
different configuration of the machines involved in the process from that used for
protein identification.

1.3.3. The egg and chicken problem

A problem with the interpretation of any result linked to the presence of
phosphoinositide rich domains is the experimental determination of the cause for such
a domain. These could potentially come from membrane properties that enhance
phosphoinositide localization to the areas with the appropriate curvature, but could also
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be driven through protein interactions with phosphoinositides and posterior protein
aggregation driving the phosphoinositide enrichment 31. Both situations can occur
simultaneously and several proteins can be involved, thus determining a specific cause
for an area rich in a phosphoinositide can be very complicated, especially since the
processes do not occur in isolation from other processes involving phosphoinositides.

1.3.4. Manipulation of phosphoinositide abundance

Genetic modifications to the proteins that interact with phosphoinositides have been
one of the most commonly used tools for their study. Genetic modifications can be very
simple and provide clear results such as the demonstration of the osmo-protective role
of myo-inositol-1-phosphate (MI1P) for growth in elevated salinity environments. This
work was done by expressing the gene for the synthesis of MI1P (PcINO) obtained from
Porteresia coarctata (a wild plant related to rice) in E. coli, Schizosaccharomyces pombe,
and plants from the genus Oryza (rice) and Brassica (mustard and cabbage). The
experiment showed that the expression of the MI1P-synthase allowed them to growth
under normally inhibitory salt concentrations. Since E. coli does not have the ability to
synthesize myo-inositol this allowed to confirm it was MI1P that provided the salt
tolerance and not the synthase itself since the growth of the bacteria showed a dose
response to the myo-inositol added22.
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Genetic labeling with fluorescent proteins of the enzymes involved in phosphoinositide
synthesis or degradation is a common practice. In the best cases co-localization of the
labeled phosphoinositide binding domain and the enzyme responsible for its synthesis
can be evaluated simultaneously by using a labeled enzyme and a labeled
phosphoinositide binding domain. PIP2 and a PI4P-5-kinase were shown to co-localize to
nuclear speckles135 suggesting that PI4P should also be localized there. This approach
has the same caveats as using the phosphoinositide binding domains since the enzyme
might interact with a lot more proteins thus their localization does not necessarily imply
the presence of phosphoinositides. As mentioned earlier the tumor suppressor PTEN is a
good example of an enzyme which active site is known to dephosphorylate both
peptides and phosphoinositides176.

Basic approaches including knock-outs have been particularly fruitful in yeast. By
selectively deleting the parts of the sequence that control the nuclear or cytoplasmic
localization of Pik1, a PI4-kinase, it was possible to show that it is necessary for viability
in both locations, and this was confirmed by the rescue of viability only when
constitutively cytoplasmic and constitutively nuclear forms were expressed
simultaneously59. Mouse knock-downs have also been carried out and there are a
significant number of human diseases linked to loss of function of enzymes involved in
phosphoinositide metabolism. The interpretation of these is however hampered by the
difficulty in ascribing specific functions given the possibility of compensation for the
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production of a phosphoinositide from an alternative pathway or the lethality of the
mutations5, 169.

Overexpression of enzymes involved in phosphoinositide metabolism is an approach
that has also provided useful information. While the approach suffers from the same
problem most genetic screens do when dealing with phosphoinositides, the possibility
of alternative compensating pathways, very important insights have been gained in this
way. The characterization of a second PIS in Arabidopsis was done in this way for
example. Through fluorescent labelling it was shown that both PIS enzymes (PIS1 and
PIS2) localized to the ER and in a lower amount to the Golgi apparatus. In vitro activity
showed a difference in the preference for different fatty acids in the CDP-DAG from
both synthetic and plant derived origins with PIS2 preferring unsaturated fatty acids
while PIS1 used mostly saturated or mono-unsaturated ones. Overexpression of each of
the enzymes showed very different patterns in other lipids. While PIS2 generated
significantly higher levels of PI4P and PIP2 the levels of these remained normal with
overexpression of PIS1 which instead led to higher levels of phosphatidylethanolamine
and DAG50. This study is exceptional because it suggests a mechanism of regulation of
phosphoinositide metabolism by the fatty acid tails of the phospholipid, and because
the tests were performed in-vivo.

Changes in the localization of enzymes involved in phosphoinositide metabolism can be
achieved with the use of rapamycin and dimerization domains that depend on it for
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their interaction. As an example, localization of the PI4-phosphatase Sac1 to the Golgi
was shown to inhibit exit of cargo to the plasma membrane and endosomes and change
the localization of some proteins and dynamics of PIP2 at the plasma membrane 180. A
caveat of the use of rapamycin is the fact that its target is mTOR (mammalian target of
rapamycin) is already involved in phosphoinositide metabolism through the PI3K
pathway, thus it has the potential to produce significant undesirable side effects 169.
Nonetheless this has been a very useful tool providing insights into many of the
phosphoinositides roles in the cell.

Electrogenetic and optogenetic manipulations present a new set of tools that allow the
same type of approach as rapamycin induced localization but with potentially more
control on the system. A voltage sensitive phosphoinositide phosphatase from Ciona
intestinalis opened the door for the manipulation of some phosphoinositides upon
membrane potential changes. Its specificity is controlled by the magnitude of the
change in membrane potential allowing for a more precise tuning of its phosphatase
activity from the 5th position of the inositol ring upon activation to the 3 rd position with
a higher voltage (0 mV and 60 mV respectively)181. The mechanism for this activation
and change on preferred substrate has been recently described by showing there are
two sequential active states on which the protein can be depending on voltage 182. The
approach however has the caveat that it can only be used at the plasma membrane, and
it is not really specific to a phosphoinositide but a position in the phosphoinositide ring.
This has been addressed in one case by coupling it to a native phosphatase to acquire a
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more realistic control of its activity using the PTEN phosphatase 183. Optogenetic
manipulations rely on the use of protein domains that dimerize upon illumination from
specific wavelengths, allowing the localization of a phosphoinositide kinase or
phosphatase domain to the cellular localization of interest in a relatively fast (seconds)
and reversible (few minutes) manner184, 185. This approach has also been used to
activate signaling pathways involving phosphoinositide and GPCRs 186. The main problem
with them, which is also common to the use of rapamycin, is the potential activity the
soluble phosphatases or kinases might have before being localized, creating an
abnormal basal cell state. Additionally the use of some wavelengths to control the
system restricts those available for visualization with fluorescence microscopy but that
is only a minor caveat169.

Pharmacological manipulation of the enzymes involved in phosphoinositide metabolism
is also possible in several cases, with the majority of attention focusing on PI3-kinases
since PTEN is a PI3-phosphatase that is implicated in a variety of cancers 187. The main
problem with inhibitors of PI3-kinases is the lack of specificity and the presence of
resistant isoforms188. The problem with lack of specificity is shared by PI4-kinase and
PI5-kinase inhibitors, and the drugs specificity is also only present in very narrow
concentration ranges thus their value is mostly for in vitro studies 169. Nonetheless
pharmacological inhibitors of phosphoinositide metabolizing enzymes present a very
active area of research given their potential for treatment of several cancers and
immune diseases187, 189.
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Small molecules that directly bind to phosphoinositides preventing their interactions
with proteins while minimizing undesired effects on other proteins or phosphoinositides
are starting to be researched. A membrane soluble molecule that binds to PIP2 was
developed and shown to be well tolerated by fibroblasts (3T3 cell line) in culture
modifying both cytoskeletal dynamics and receptor endocytosis. This molecule shows
preference for PIP2 over IP3 (the head-group of PIP2 without lipid tails) which is the
opposite of the behavior in PIP2 binding proteins190. While this is an isolated approach it
might represent a new avenue for the creation of tools to control phosphoinositide
abundance.

On the reverse approach, membrane permeable phosphoinositide analogs in which the
phosphate and hydroxyl groups are respectively masked with acetoxymethyl esters and
butyrates have been developed. Once in the cytosol unspecific carboxyhydrolases turn
the molecules into “normal” phosphoinositides191. This approach has been extended to
unnatural phosphoinositides which are also phosphorylated at the 6 th position, although
the results obtained with this approach couldn’t be interpreted mechanistically 192. Since
the carboxylases are relatively slow to release the phosphoinositide analog, a caged
version was developed in which the molecule can diffuse and accumulate in the
cytoplasm in the caged state until photoactivated and released to go into
membranes193. This approach allows for more precise control at both the temporal and
spatial scales. Nonetheless there is no control over which membrane the
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phosphoinositide analogs integrate potentially complicating the interpretation of results
obtained using them169. The fatty acid tails used in these phosphoinositide analogs are
also typically short192 and while the regulation of phosphoinositide activity by the lipid
tails remains largely unexplored this could add another level of complexity to the
interpretation of experiments using the analogs.

Finally pathogens have provided alternate evidence for some of the functions of
phosphoinositides. The intracellular pathogen Shigella uses several protein effectors in
order to remodel the actin cytoskeleton and successfully carry out infection. Of this IpgD
is a phosphoinositide phosphatase that produces PI5P showing a preference for PIP2 as
its substrate but also from other phosphoinositides194. Salmonella, another intracellular
pathogen has a homolog of IpgD called SopB which prefers PI(3,4)P2 and PIP3 as its
substrates195. In the case of SopB the function of the protein seems to be a general one
depending on changes of the charge of the membrane of the vacuole containing the
bacterium since it not only alters phosphoinositides but also reduces
phosphatidylserine. The change in the membrane prevents the vacuole from fusing with
lysosomes196. It is however complex to adjudicate this results exclusively to charge since
there is no methodology available to in-vivo separate the specific binding of proteins to
phosphoinositides to that based only on charge interactions.

IpgD however seems to be more specific in its pathogenic role and was shown to
regulate the trafficking of ICAM-1 (intercellular adhesion molecule-1) in a manner
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dependent of its phosphatase activity and PI5P production. This in turn leads to less
neutrophil adhesion reducing the immune response to the pathogen 197. The role of PI5P
in endosomal trafficking has been described for other receptors, such as the epidermal
growth factor receptor (EGFR), and shown to be dependent on the adaptor protein
TOM1( target of myb-1 originally described from chicken) by using IpgD as a tool for the
enrichment of PI5P198. PI3P has been shown to be important for Plasmodium
pathogenesis29, both for its own trafficking of ingested hemoglobin and in the host cell
where one of its effectors is a promiscuous PI3-kinase but which functions are less well
characterized199. There is evidence suggesting PI3P is present on the outer leaflet of the
plasma membrane of some plant and animal cells where it is used by fungal and
oomycetes effectors for internalization 30. The authors of this study used
phosphoinositide binding domains that are specific for PI3P labeled with fluorescent
proteins for their assays and as a negative control showed that this construct didn’t bind
to erythrocytes which act as a control for unspecific binding. A PI4P binding domain also
showed no accumulation on the evaluated cells outer membrane leaflet suggesting that
the results are valid. How PI3P would be localized to the plasma membrane in the first
place remains unexplored and highlights the fact that our knowledge of
phosphoinositide biology is still limited.

Given the vast array of functions phosphoinositides are part of, and the complexity in
studying them, it has been proposed that a network approach that includes both
proteomic and interatomic analyses might help elucidate their functions better. This
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would help build a clearer picture about the different functions of isoforms of the same
enzymes. Such an approach would also allow using the phenotypes observed in the
diseases linked to mutations in the enzymes involved in phosphoinositide metabolism to
better inform knowledge of their functions and potentially identify medical targets5.
While this definitively seems to be a very promising avenue for research it has remained
largely unexplored.

1.4.

Reason and goal for this thesis

The study of phosphoinositides represents an area of science where the intrinsic
complexity of the system requires the slow tuning of our mechanistic models through
many independent lines of evidence. It is clear that the phosphoinositides are involved
in a wide variety of functions that they perform though their interactions with proteins
in a finely tuned manner, and through many detailed experiments we have several
mechanistic models for some of the processes that involve phosphoinositides. Direct
evidence is however very hard to obtain for most functions since the controls available
are not ideal and, given the multiplicity of functions phosphoinositides have, it is not
possible to demonstrate sufficiency of a set of components for a process. This is because
of the possibility of interference with other pathways in the cell that involve some of the
same phosphoinositides or proteins. An additional problem is the possibility of
compensation for any experimental alteration by alternative phosphoinositide
metabolic or trafficking pathways.
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While in vitro experiments present a good alternative to demonstrate the sufficiency of
the components of a model, in vitro systems lack the complexity of the highly diverse
living membranes. Artificial membranes do not fully reproduce the dynamic processes
and complexity observed in living cells200. With this in mind I set to develop a new
platform for the in-vivo study of phosphoinositides without the possibility of cross talk
or interference with other processes that involve them.

In order to do so I have developed a system that takes advantage of the lack of any
phosphoinositides in the bacterium Escherichia coli201 to prevent any interference from
other processes while allowing researchers to perform experiments in-vivo. By
engineering this bacterium to synthesize the phosphoinositides of interest it is possible
to build new systems based on mechanistic models of phosphoinositide functions and
demonstrate the sufficiency of a set of components for a process in-vivo. While this
platform does not address the necessity of the set of components used for the actual
process being evaluated it provides with a fully independent line of evidence to
complement other types of experiments and advance our knowledge of
phosphoinositide biology.
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1.5.

Design decisions for the new platform

To systematically test all of the possible combinations for designing such a platform
would require an enormous amount of work. Thus I made several design decisions at
the start of the project, most of which worked satisfactorily.

The first one was to use the gram negative bacterium Escherichia coli as the cell upon
which to build the system. The reason for this choice was the assumption that by being
one of the most well characterized organisms the tools available to build the system,
and thus its utility would be maximized. E. coli is known not to have any endogenous
phosphoinositides since classical experiments intended to find them 202 and this remains
the case in recent experiments201, thus it is perhaps the best candidate organism to not
have any phosphoinositides. While this sounds like an extreme precaution it is not
without reason; until very recently it was thought that phosphoinositides only occurred
on few bacteria while now they are known to be present in a significant number of
bacterial clades3. Another advantage of using E. coli is the availability of tools for protein
expression, and in particular for multiple protein co-expression203.

The second design decision was to focus on PIP2 as the phosphoinositide of interest
with PI, PI4P as its precursors. While the system can be expanded in the future to other
phosphoinositides limiting it to just these 3 allowed for a simpler biochemical pathway
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to be needed. Additionally given these are the most abundant phosphoinositides in
mammalian cells25 the potential applications for the system are maximized.

The other design decisions refer to the expression of the enzymes necessary and the
control of phosphoinositide abundance. Since the goal of the system is to build a
platform that can be used to recreate diverse models for cellular processes I decided to
minimize the use of any protein expression tools such that most would be available to
potential users of the system. To do so I chose to express the enzymes required for the
phosphoinositide synthesis in a constitutive manner, using inositol as a way to control
the system since it can be added to growth media. This choice means all inducible
protein expression systems will be available to any potential user of the system. All
enzymes were labeled with the same peptide tag to ease their identification with a
single antibody, thus also leaving all other commonly used tags free for use by users of
the system. Additional by putting all enzymes on the same plasmid only one antibiotic
marker and only one of the 4 families of compatible plasmids 203 is used leaving 3
plasmid origin families and all but one antibiotic resistant markers available for users of
the system.
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2. Materials and Methods

2.1.

Description of the system

Because of the nature of the system I have combined its description with the methods
section in order to better illustrate why certain optimization steps were required. The
designed metabolic pathway is illustrated in Figure 3A. The first step, synthesizing PI, is
catalyzed by phosphatidyl inositol synthase (PIS) from the lipid cytidine diphosphatediacylglycerol (CDP-DAG) and myo-inositol. Cytidine diphosphate-diacylglycerol is
present naturally as the precursor of E. coli’s phospholipids204 and myo-inositol can be
added to growth media of E. coli expressing Trypanosome brucei PIS to synthesize PI invivo205. This enzyme was kindly provided by Dr. Terry K. Smith of The University of St
Andrews, UK. Using this enzyme gave me the advantage of starting from a system that
was already characterized for the production of PI, and in which inositol was known to
be a viable way to regulate the system in vivo. While it is not clear how inositol will
reach the cytoplasm of the bacterium, I did not try to investigate the mechanisms since
the previous work had shown its addition to the media leads to the production of PI.
Thus for the purposes of my system the relevant factor is that inositol is incorporated,
although the mechanisms is unknown.

The next two steps involve the phosphorylation of PI at the 4 th and 5th positions, by
phosphatidylinositol 4- kinase and phosphatidylinositol 4-phosphate 5-kinase
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respectively206. To my knowledge these enzymes have not been shown to be active invivo when expressed in E. coli, so I used enzymes that had been previously expressed in
this bacterium and showed activity when purified. I used Bos taurus (cow)
phosphatidylinositol 4-kinase β 207 (PI4Kβ, PI4K henceforth) kindly provided by Dr.
Tamas Balla of the Program for Developmental Neuroscience at NIH, and human
phosphatidylinositol 4-phosphate 5-kinase type-1 α isoform 2 (PI4P5Kα henceforth
PI4P5K)208 kindly provided by Dr. Richard A. Anderson of the University of Wisconsin Madison. When choosing these enzymes I assumed that given they are active after
production and purification from E. coli they should also show activity in the bacterium.
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Figure 3. Phospholipid metabolic pathway in E. coli and modifications for
phosphoinositide production
A) E. coli phospholipid metabolic pathway and designed PIP2 synthesis pathway.
B) Construct for the expression of the enzymes required for PIP2 synthesis.
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2.2.

Laboratory methods

To build the system I used a combination of traditional restriction enzyme cloning, site
directed mutagenesis, artificial synthesis of DNA, and assembly PCR. For the site
directed mutagenesis I used the QuikChange Lightning site directed mutagenesis kit
from Agilent Technologies according to the manufacturer protocol but scaling down the
volume to 25, 15, or 10 μl per reaction instead of the recommended 50 μl. All primers
used were obtained from Integrated DNA Technologies and designed manually.
Restriction enzymes were acquired from New England BioLabs and used according to
their protocol. Ligations were performed with the Quick Ligation Kit also from New
England BioLabs following their protocol. PCRs were performed using the Platinum PCR
SuperMix according to manufacturer protocol or the AccuPrime Pfx SuperMix when
blunt ends were required or for the assembly PCR; both of these mixes were from
Invitrogen (now Thermo Scientific). Artificial DNA synthesis was obtained as a service
from GENEWIZ. All purification steps were performed using the DNA Clean &
Concentrator-5 from Zymo Research, and agarose gel purifications were performed
using Zymoclean Gel DNA Recovery Kit from the same company. Plasmid purification
was performed with the PureLink Quick Plasmid Miniprep Kit from Invitrogen.

No DNA sequence optimization was performed on the enzymes except on PI4K, which
had 3 translation pause sites specific to E. coli209 which I removed. On PI4K I also
modified the 5’ end to eliminate possible loops in the RNA that could affect translation. I
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identified the loops using the RNAfold web server from the Institute for Theoretical
Chemistry at the University of Vienna (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi).
The changes amount to a total of 10 synonymous point mutations to the enzyme,
focused on its N terminus. Since the expression and activity of this enzyme was
satisfactory after all these changes I did not attempt to isolate the effects of each
individual change or to fully codon optimize the sequence and moved forward with the
modified enzyme. A file with the final construct fully annotated is provided as the
Supplementary File 1, and the sequence will be uploaded to NCBI upon publication of
the paper describing this work. All constructs were fully sequence verified by Sanger
sequencing using GENEWIZ services.

Originally the plasmids used for this study were built in lab based on plasmid pET151
from Invitrogen, which has an origin of replication from the ColE1 family. Because
during optimization I had to switch to a lower copy plasmid the final constructs were
built based on an origin of replication from the P15A family, obtained from the plasmid
carried by E. coli BL21-CodonPlus(DE3) from Agilent Technologies. This strain was not
used in my experiments and only the origin of replication obtained from the plasmid it
carries was used. When a second compatible origin of replication was needed for the
experiments, I used a plasmid built with an origin of replication from the ClodF13 family
obtained from plasmid pCDFDuet-1 MKK4(EE)-MKK7a1(EE) which was constructed by
Dr. Kevin Jane’s research group and purchased from Addgene (plasmid # 47580). All
plasmids used are presented in Table 1.
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Cloning procedures were performed in E. coli strain DH5α since this is the routine strain
for this purpose, using chemically competent cells. For all the experiments the E. coli
strain BL21 DE3 was used since this is a strain commonly used for the expression of
exogenous proteins in this bacterium taking advantage of the inducible T7
polymerase210 and thus is likely to be most useful to users of the system. Note that the
system I developed does not require the T7 polymerase and should work in any E. coli
strain. In order to make chemically competent cells for my experiments I used the Mix &
Go E. coli Transformation Kit from Zymo Research according to manufacturer’s protocols
which follows a standard chemical competence protocol 211. Strains of E. coli were
obtained from Invitrogen (Thermo Scientific). All bacteria were grown in LB media at
37C in an orbital shaker at 260 rpms.

In order to make the measures most consistent, BL21 DE3 cells for experiments were
transformed with the appropriate plasmids and plated on LB agar with the appropriate
antibiotics. After a day a single colony was picked and grown overnight in LB media with
antibiotic, and then diluted to an OD600 of 0.05 in fresh media with the appropriate
antibiotics and inositol if required for the specific treatment. Liquid cultures were grown
in 14 ml tubes filled with 6ml of media unless indicated otherwise. Except for time
course experiments, cells were always grown for 3h or less for experiments after the
initial dilution to guarantee that they would be in the exponential growth phase, thus
diminishing cell to cell variability.
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For lipid extractions a volume of culture was pelleted to be equivalent to 10 ml of
OD600 equal to 1.0. For protein extractions the same protocol was used but using only 1
ml volumes and only one fourth of the extraction was loaded to the polyacrylamide gels.
Protein extraction was performed using the BugBuster 10X Protein Extraction Reagent
from Millipore supplemented with rLysozyme Solution and Benzonase Nuclease, Purity >
90%, also from Millipore according to manufacturer protocol. For Western blots 9E10
antibodies were obtained from Acris Antibodies (now part of Origene).

To measure the growth rate of the cells an overnight culture of bacteria was diluted to
an OD600 of 0.05 and 300 μl were grown in a 96 well plate incubated at 37C in a plate
reader. OD600 was measured every 30 minutes. Each strain was measured in 4
independent wells and a correction was performed for evaporation on the blank well.
The slope of the linear approximation to the middle of the exponential phase of growth
was measured for each well and this slope is the data gathered to perform the
averaging. For morphology observations 1 μl of bacterial culture was spread in a glass
slide, covered with a cover slip and bright field images were obtained with a 60x water
objective with a 1.5x objective in the light path (90x total).
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Table 1: Plasmids used in this work
Plasmid type 1
P15A family origin of replication (10-12 copies per cell), chloramphenicol resistance,
constitutive promoter D, N-terminal myc tag
Name

Insert

Notes

p15aC

None

Empty plasmid control

p15aC-GFP

GFP

Control

p15aC-1D

PIS

p15aC-4D1D

PI4K and PIS

p15aC-1D-5

PIS+PI5P5K

Enzymes expressed with separate
repeated promoters
Enzymes expressed as an operon in
that order
PI4K expressed separate and

p15aC-4D1D-5

PI4K and PIS+PI5P5K

PIS+PI5P5K expressed as an operon in
that order with repeated promoters

Plasmid type 2
ClodF13 family origin of replication (20-40 copies per cell), ampicillin resistance, dual
constitutive promoter D, cytoplasmic mCherry, N-terminal GFP tag
Name
pClodACherryPIP2PH-GFP

Insert

Notes

PLCδ-PH domain
PLCδ-PH domain with

pClodACherryPIP2PHmutant-GFP

mutant binding site:
K30A, K32A, W36A,
R40A, E54A, S55A,
R56A, K57A

pClodACherryPI4PPH-GFP

OSBP-PH domain
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Failed construct (see text)

Table 1: Plasmids used in this work (continued)
Plasmid type 3
ClodF13 family origin of replication (20-40 copies per cell), ampicillin resistance,
constitutive promoter D, C-terminal NanoLuciferase tag
Name

Insert

pClodANL-Cherry

mCherry

pClodANL-

FGF2 non-binding mutant

NonBinderFGF2

K127Q,R128Q, K133Q

pClodANL-wtFGF2

FGF2 wild type

pClodANL-FGF2-Y82E

FGF2 Y82E phosphomimic

pClodANL-FGF2-Y82EE

Notes
Control

FGF2 Y82EE double
phosphomimic

Plasmid type 4
ColE1 family origin of replication (~40 copies per cell), chloramphenicol resistance,
constitutive promoter T7 and promoter D in tandem, N-terminal myc tag, enzymes
expressed as operon in order indicated. These were used as optimization intermediates
Name

Insert

pET151Cons1

PIS

pET151Cons41

PI4K+PIS

pET151Cons51

PI4P5K+PIS

pET151Cons54

PI4P5K+PI4K

pET151Cons541

PI4P5K+PI4K+PIS

pET151Cons145

PIS+PI4K+PI4P5K
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Notes

Reverse order operon,
showed better activity

Lipid extraction was performed with the Bligh-Dyer protocol212 adapted specifically for
this project (see Supplementary Protocol 1). Lipids were stored at -20C and measured
the next day after extraction since degradation was observed over time in the
optimization runs. PI4P and PIP2 abundances were measured using a competitive ELISA
assay commercially available from Echelon Biosciences. On the day of the ELISA tests an
aliquot of 6 μl or less of the extracted lipids was dried by leaving a 1.5 ml
microcentrifuge tube open for 10 to 15 minutes and resuspended according to the ELISA
protocol.

In order to do the calculations of the percentage of lipids in the cell being
phosphoinositides I used a relationship between total biomass of E. coli and optical
density of the culture determined previously213. This equation defines the dry weight of
E. coli growing in LB media as 0.56 by the OD660 in grams per liter, thus: Dry weight (g/l)
= 0.56 x OD660. The percentage of lipids in E. coli by dry weight has been estimated at
9.1%214 so an estimate can be made for the total lipids in the cell given the measured
OD. These values were found using the BioNumbers database 215 with their ID numbers
being 108127 and 101938 respectively. In order to estimate the quantity of
phosphoinositides relative to the overall lipids in the cell, an assumption on the molar
weight of the phosphoinositides needs to be made since the precise lipid tails are
unknown. I used values of 800 and 850 g/mol for PI4P and PIP2 respectively, which
correspond to a phosphoinositide with the shorter lipid tails characteristic of E. coli.
While this is by no means a precise calculation, it allows for an estimate of the range of
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phosphoinositides being produced in the cells. This estimate is good enough to evaluate
the potential of the system to build mechanistic models of eukaryotic cell biology.

For the phosphoinositide localization tests I used the PH domain of oxysterol-binding
protein (OSBP-PH domain) which binds PI4P 216 and the PH domain of phospholipase
Cδ1 (PLCδ-PH domain) which binds PIP2217. These constructs were kindly provided by
Dr. Tamas Balla of the Program for Developmental Neuroscience at NIH. The
expectation for these tests is that the cells should show diffuse fluorescence in the
cytoplasm when no phosphoinositides are being produced, and a halo should appear
when phosphoinositides are present indicating the localization of some of the labeled
protein to the plasma membrane. As a way to have an internal control I also expressed
mCherry, a red fluorescent protein, such that in the same cell I could observe the
behavior of the tagged phosphoinositide binding PH domain in the green channel and a
control in the red channel. To perform these analyses with the appropriate resolution I
used a LEICA scanning confocal microscope. I set the aperture of the pinhole to 1 airy
unit relative to the fluorescence of GFP at 507 nm (in this case 1 airy = 128 μm), and
excited sequentially with a laser at 488nm for GFP and 587 nm for mCherry, acquiring
on the range of 500 to 570 nm for GFP and 600 to 670 nm for mCherry. For imaging I
used a 100x HC PL APO oil objective of 1.44na. The image size was a square of side 29
μm at a resolution of 512x512 pixels, scanned at 100Hz.
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Detection of the enzymes expressed in the system using the myc tag proved
problematic initially. Polyclonal antibodies showed poor performance, with many nonspecific bands appearing. This is presumably due to imperfect affinity purification
combined with the use of proteins expressed in E. coli for the immunization of animals.
Since the myc tag is a very commonly used tool there are monoclonal antibodies
available which should have solved the issue. Of these the clone 9E10 from mouse
showed the best results, but surprisingly only when the antibody is directly labeled with
horse radish peroxidase (HRP). When the 9E10 monoclonal antibody is used with a
secondary antibody a western with very little or no noise is obtained but only PI5K is
detected. Figure 4 shows a comparison of the 9E10 antibody with its HRP tagged version
when used to detect the construct expressing PIS and PI4P5K in both nitrocellulose and
PVDF membranes.
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Nitrocellulose

PVDF

Nitrocellulose

PVDF

191
97

PI4P5K
~60kDa

64
51
39
28

PIS
~24kDa

19
kDa

9E10-HRP

9E10 + secondary

Figure 4. Comparison of the 9E10 monoclonal labeled and unlabeled antibodies
Untagged and tagged versions of the monoclonal antibody 9E10 were used for the
detection of PIS and PI4P5K simultaneously in both PVDF and Nitrocellulose
membranes. This comparison shows the best detection of the enzymes is obtained
when using the HRP labeled antibody in a nitrocellulose membrane.
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For NanoLuc Luciferase assays cells were grown in the same way as for the other
experiments and at 3h 50 μl of culture were pipetted to a well in a 96-well plate. 30 μl of
freshly made PBS pH 7.0 containing 30 μl of substrate (Promega N113A) per 10 ml of
buffer were added to each well and luminescence and OD600 were measured. After this
initial measure 100 μl of BugBuster 1X prepared in PBS pH 7.0 were added to each well
and lysis was allowed to run for 15 minutes. Lysis was confirmed by the decrease in
OD600 in the well reading. After lysis 20 μl of PBS pH 7.0 containing 20 μl of substrate
were added to each well and luminescence was measured again. All measures were
performed immediately after substrate addition to guarantee substrate excess and an
appropriate reading.

2.3.

Optimization of the system

I initially attempted to build an operon expressing the 3 enzymes required for PIP2
synthesis from the same RNA. However, expression of PI4-kinase was problematic and a
system in which PIS and PI4P5-kinase were expressed in that order as an operon, and
PI4-kinase was expressed separately was necessary for detection of all 3 enzymes on
western blots. This was assembled in the same plasmid, using the same promoter and
terminator for both PI4-kinase and the PIS-PI4P5-kinase operon. Each of the enzyme
sequences is preceded by a ribosome binding site (RBS) designed with the RBS calculator
software to maximize their expression218, 219, and has an N-terminal myc peptide tag
(amino acid sequence EQKLISEEDL) for easy identification in western blots. To prevent
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possible recombination between the repeated promoters the origin of replication and
the resistance marker were arranged in such a way that if recombination happens the
resulting plasmids would lack either a promoter or an origin of replication and be
therefore selected against. A schematic of the final expression system is shown in Figure
3B.

In the initial steps of optimization of the system I attempted to use a modified version of
the plasmid pET151 (from Invitrogen) changing the resistance marker to
chloramphenicol. Plasmid pET151 has a medium-high copy number (~40 copies per
cell)203. I left the very strong T7 promoter210 directly followed by the promoter selected
for the system (see description of the final system below). This system led to
morphological abnormalities in the bacteria (see Figure 5A), presumably due to overly
high protein expression levels causing aggregation. An additional abnormal phenotype
in which cells became very long also appeared when growing with PIS and PI4P5K
together (note the lack of PI4K) in minimal media supplemented with inositol (Figure
5B). Some long cells are observed even in control cells so a small fraction of long cells in
any construct is normal, but in this case it is the majority of the cells that are long with
most of them being extremely long. This phenotype only appeared as extreme in this
media and only for this construct so I suspect it to be an interaction between the level of
phosphoinositides present and the amount of the exogenous proteins potentially
interfering with correct localization of E. coli’s membrane bound proteins under the
stress of growing on poor media. In one occasion the high expression of PIS alone did
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produce some very long cells in LB media supplemented with inositol, but those were
less than 20% of the cells (Figure 5C). Since I did not use these constructs and built a
working system using another origin of replication I did not investigate any of these
abnormalities further.

I built the final system using a low copy plasmid with an origin of replication from the
P15A family, and a chloramphenicol resistance marker. There was no specific reason to
choose this over other antibiotics except ampicillin. Since ampicillin is the most
commonly used antibiotic I wanted to use one that would allow more of the already
available constructs to work in the system without modifications. The origin of
replication used has a low copy number of 10-12 copies per cell203, and I used an
insulated constitutive promoter that expresses robustly in E. coli, named promoter D in
the work of Davis and co-workers220, henceforth simply referred to as promoter. A
schematic of the final expression system is shown in Figure 3B. Since the promoter
works in E. coli without needing specific exogenous polymerases (such as the commonly
used T7 promoter) the system can be used in any strain of this bacterium. In order to
make the system most useful and maximize its uses I created versions of the plasmid
expressing only PIS, PIS plus PI4K, and PIS plus PI4K and PI4P5K, thus producing PI, PI
plus PI4P, and PI plus PI4P and PIP2 respectively. Additionally, I constructed control
plasmids expressing only a myc-tagged green fluorescence protein or just the myc tag.
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A

Control

PIS

PIS + PI4K

PIS + PI4K + PI4P5K

LB media

C

B

PIS + PI4P5K

PIS

Minimal media with 2mM inositol

LB media with 2mM inositol

Figure 5. Abnormal morphology of cells with high expression constructs
Overnight cultures were diluted to an OD600 of 0.05 and grown for 3 hours in LB or
minimal media supplemented with inositol and the appropriate antibiotics. A)
Morphology in LB media. While a larger cell size is normal in E. coli overexpressing
protein, I observed several other abnormalities in LB media even without the addition of
inositol. B) Extreme abnormal growth observed in E. coli expressing PIS and PI4P5K in
the grown in minimal media supplemented with inositol. C) Low frequency abnormal
growth of E. coli expressing PIS in LB media supplemented with inositol.
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3. Results and discussion

3.1.

Characterization of the system

All enzymes were expressed as expected in the final construct (Figure 6, Figure 7 shows
the same western on a PVDF membrane) but there are a large number of faint
nonspecific bands appearing in the western. While generally these can be thought of as
degradation or incomplete translation products some of them increase in size relative to
the enzymes expressed and likely reflect a more complex situation like the modification
of the enzymes by the bacterium or possibly the induction of expression of endogenous
proteins from E. coli that share the recognized peptide. Since the pattern of expression
is the expected one and the functional tests showed the production of the
phosphoinositides of interest I did not try to optimize the system further to reduce
these nonspecific/degradation product bands.
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Figure 6. Western blot confirmation of enzyme expression on nitrocellulose
Western blot detection of the enzymes in the final constructs using an HRP labeled 9E10
antibody against myc peptide on a nitrocellulose membrane. Note that constructs
expressing PI4K show bands significantly higher than expected and the PI4K band itself
is odd showing more signal towards the edges than the center of the lane. The protein
sizes indicated include the myc tag and spacers.
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Figure 7. Western blot confirmation of enzyme expression on PVDF
Western blot detection of the enzymes in the final constructs using an HRP labeled 9E10
antibody against myc peptide on a PVDF membrane. Note that constructs expressing
PI4K show bands significantly higher than expected and the PI4K band itself is odd
showing more signal towards the edges than the center of the lane. Also detection of
PIS is not consistent among constructs. The protein sizes indicated include the myc tag
and spacers.
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The system showed no adverse effects on growth (Figure 8) of the cells expressing the
enzymes regardless of inositol addition up to 10mM when growing on LB media.
However, 20mM of inositol proved lethal for all constructs except the control. This could
be due to a lethal effect of the phosphoinositides themselves or to competition for the
CDP-diacylglycerol precursor. Since the effect is observed even when just PI is produced,
it should be due to the properties of PI directly or to the competition effect and not to
the high charge of PI4P or PIP2. If the effect is due to PI it would likely be due to its
bulkier head-group compared to the normal E. coli phospholipids. For the purposes of
my system this lethality effect imposes a limitation of maximum 10mM inositol in the
media. I performed all experiments using at most 5mM inositol in the media with 2mM
being the concentration used for most experiments. Larger cell size is normal in E. coli
overexpressing protein221, so when judging changes induced by protein expression it is
important to consider that a larger size is not an abnormal situation. The morphology of
the cells expressing the different constructs was normal when growing in LB media with
2mM inositol (Figure 9). In some of the tests expressing other proteins cell size did
increase (see the “no inositol control” in Figure 15 for an example), but the cells never
behaved in an aberrant way such as that observed during the optimization runs in the
high expression system (see Figure 5).
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Figure 8. Effects of constructs and inositol on the growth rate of E. coli
Cells were grown in 300 μl of media in a plate reader measuring OD600 every 30
minutes. Note the lethality of the treatment of 20mM inositol for all constructs except
control (red circles). Data shown is the average of 4 independent measures with error
bars showing the standard deviation of the sample.
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Figure 9. Normal morphology in E. coli producing phosphoinositides
Cells were grown for 3h in LB media with chloramphenicol and with or without inositol
depending on the treatment. Scale bar is 2μm.
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Since PI had been produced and characterized in E. coli by other researchers205 and its
role seems to be only structural and as a precursor of phosphorylated phosphoinositides
I did not characterize the PI further, and only characterized the production of PI4P and
PIP2. The goal of the project is to allow the study of PI4P and PIP2 functions, with a
focus on PIP2. Initial tests of the effects of different combinations of the enzymes all
showed the expected behavior except for the expression of PIS and PI4P5K together in
the absence of PI4K. This construct should produce only PI but it also produced PI4P and
PIP2. This shows that PI4P5K is able to phosphorylate PI at the 4 th position creating PI4P,
its normal substrate, which it then phosphorylates again generating PIP2. The fact that
PI4P can be detected implies that the phosphorylation is not carried in tandem but that
the enzyme must release PI4P at least a fraction of the time. While it is a surprising
finding, it is beyond the scope of this project to investigate it further and I prefer not to
speculate about its potential biological meaning. Since the system lacks any of the
normal regulators of activity for this enzyme, and there is no spatial segregation by an
endo-membranous system, this activity might in fact be specific to my system.
Nonetheless this construct was included when characterizing the amount of
phosphoinositides produced since it may offer an alternative for users of the system
that would like to minimize the metabolic stress of exogenous protein expression to the
bacterium. Using this construct it is possible to have a cell with PI, PI4P and PIP2 present
while only expressing two enzymes (PIS and PI4P5K).
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Figure 10 shows the production of PI4P and PIP2 by the different constructs. Quantities
are indicated as percentage of the total lipids by mass since this allows for the most
direct comparison to the levels of phosphoinositides Eukaryotic cells. The range
observed is on the lower end of the range observed in mammalian cells, in which PI4P or
PIP2 each represents about 0.5-1% of the total phospholipids. Considering that in
eukaryotic cells phosphoinositides interact with a wide variety of proteins at all times
the amount of free phosphoinositides in these cells should be significantly lower, thus
the amount produced by the system I developed should be enough to test most cell
biology models of interest with levels of available PIP2 equal or higher than those in
eukaryotic cells.

Another consideration is the fact that E. coli has a double membrane and since
phosphoinositides do not spontaneously flip, they most likely would all be on the inner
leaflet of the plasma membrane. Although not yet characterized, the unspecific
scrambling of phospholipids in the membrane of E. coli222 could cause equal distribution
of the produced phosphoinositides on both leaflets of the plasma membrane, but given
the high charge of PI4P and PIP2 relative to normal E. coli lipids it is unlikely this would
be the case since any transporter would not normally act on highly charged
phospholipids. If phosphoinositides were to flip to the outer leaflet of the plasma
membrane it is also possible, albeit very unlikely for phosphorylated phosphoinositides
given their charge, that they could make it to the outer membrane through the normal
mechanism for translocation used by the bacterium.
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Figure 10. Phosphoinositide production for all constructs
Cells for the analysis were grown for 3h in LB media with 2mM inositol and
chloramphenicol, after which lipids were extracted as described in the text. Data shown
is the average of 4 independent measures with error bars showing the standard
deviation of the sample. Note the unexpected production of PI4P and PIP2 in the last
construct where PI4K is absent.
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Thus the estimate provided represents a conservative scenario for their abundance with
the maximum effective concentration being four times the reported one (assuming an
equal split of phospholipids between the inner and outer membranes of the bacterium
and all phosphorylated phosphoinositides residing on the inner leaflet of the plasma
membrane) and the minimum being the reported one (assuming equal distribution
among inner and outer leaflets, of both plasma and outer membranes). It is important
to note that PI4P is produced at a lower level than PIP2 even when only PIS and PI4K are
expressed. While in the constructs that produce PIP2 a lower amount of PI4P is
expected, since it will be phosphorylated to PIP2, one would expect a similar or even
higher level of PI4P when no PI4P5K is present since it should accumulate in the cell. The
fact that this is not observed suggests that PI4K might autoregulate based on the
abundance of PI4P.

The ELISA assay, used to determine PI4P and PIP2 abundances, has a first step consisting
on the resuspension of phosphoinositides in aqueous solution and its subsequent
binding by a phosphoinositide binding domain specific to the phosphoinositide of
interest. Since phospholipids are intrinsically unlikely to be in aqueous solution given
their hydrophobic tails this first step is particularly problematic and can cause abnormal
behavior in some runs of this assay. The successful runs show consistency across them
and within the trends among samples and controls, but the unsuccessful ones show no
differences among the samples and either a very low (barely above the detection limit)
or very high signal (saturated for the most part) on all samples. Customer support could
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not provide any solutions for this problem thus the test was repeated and the results
reported are only from successful runs.

As explained above, unsuccessful runs of the ELISA tests are easily detectable by the
behavior of controls, thus they can be objectively identified. In particular, the behavior
of the control system which is E. coli with a control plasmid that doesn’t express any of
the enzymes, and the control that just expresses PIS allows for the identification of any
abnormal runs. An alternative form of evidence confirming this assessment of successful
runs was initially done by a protein lipid overlay assay, which is the equivalent of a dot
blot in which lipids are dotted on a membrane and then identified with a protein 165. This
overlay assay for the detection of PI4P was also available commercially from Echelon
Biosciences but has now been discontinued and the version for the detection of PIP2
was discontinued before I started the project. This test showed that control and PIS
expressing constructs produced no PI4P. Figure 11 shows the results of one PI4P strip
test performed with some of the intermediate constructs used for the optimization of
the system. Unfortunately, these tests were performed before the system was
optimized and after the product was discontinued I could not replicate the protein lipid
overlay assay successfully even while getting the reagents from the same company. In
these failed attempts the calibration curve showed very bad results with little difference
across the same range of concentrations used in the commercial kit. The only difference
between these optimization assays and the final constructs was the higher expression of
enzymes, thus the assessment should be valid for the final optimized system.
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Figure 11. Protein lipid overlay for the detection of PI4P
Detection of PI4P produced by some of the optimization constructs. Since samples were
spotted in a complex order the organized data as well as the raw image are provided.
Note that at the time I was working with two operon constructs thus there are two tests
for a case when all the 3 enzymes are present, but their order of expression in the
operon was different.
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In order to characterize the system further I performed a time course experiment for
the construct expressing all 3 enzymes. The results of this experiment are shown in
Figure 12. In this experiment inositol is added at the start of the culture, defining this as
time 0. In this way cells should initially accumulate phosphoinositides, but at some point
the inositol in the media becomes limiting since it’s not being replaces and the
phosphoinositides per cell should start to decline by being diluted during cell division.
While the result is relatively noisy, it shows the expected pattern in which the amount
of phosphoinositide increases over time to a peak around 3 h, after which it declines
slowly.
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Figure 12. Time course of phosphoinositide production
Cells expressing PIS, PI4K and PI4P5K simultaneously were grown in LB media with 2 mM
inositol and chloramphenicol. Aliquots were extracted every hour, and diluted or
concentrated to obtain a pellet equivalent to 10 ml of culture at OD600 = 1 for lipid
extraction. Trend curves are from a second order polynomial. Data shown is the average
of 4 independent measures with error bars showing the standard deviation of the
sample.
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As a next step to characterize the system I performed an analysis of the effect of the
concentration of inositol in the media for the production of phosphoinositides. The
results of this test can be seen in Figure 13. This analysis showed that production of
phosphoinositides grew with increasing inositol in the media but it also saturated fast,
reaching a plateau at around 2mM inositol. This saturation indicates the system is
limited by the speed of PI production since PI4P can be produced at higher levels when
PI4P5K is not present and PIP2 is dependent upon this PI4P as a precursor. Evidently
these results, as well as the levels of phosphoinositide production and time course of
production, will vary when the system is used in different bacterial strains and/or under
different growing conditions. Their value lies in showing that the system works as
expected, and how inositol can be used to control it.
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Figure 13. Phosphoinositide production under different inositol concentrations
Cells expressing PIS, PI4K and PI4P5K simultaneously were grown in LB media with
chloramphenicol and different concentrations of inositol. At 3 hours OD was measured
and cells were diluted or concentrated to obtain a pellet equivalent to 10 ml of culture
at OD600 = 1 for lipid extraction. Trend curves are from an exponential fit of the form
-c x)

y=a+b℮(

. Data shown is the average of 4 independent measures with error bars

showing the standard deviation of the sample. When error bars are not visible it is not
because of an absence of variation but because it is too small to be seen at the scale of
the graphic.
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As a final step in the characterization of the system, and to provide alternative evidence
of the production of phosphoinositides, I used a GFP tagged phosphoinositide binding
PH protein domain. As mentioned in the introduction these are used routinely to
visualize the localization of phosphoinositides in mammalian cells 168. The advantage is
that in my system there is no possible interference by other proteins that also bind
specifically to the same phosphoinositide. A result obtained with this system will then
allow for a robust in-vivo confirmation of the production of PIP2 in my system.

For PI4P I used the OSBP-PH domain, which binds to PI4P, but this test failed, with no
membrane localization appearing even in the presence of the construct that has PIS and
PI4K growing in 2mM inositol for 3 h (Figure 14). This could be due to an insufficient
amount of PI4P but the ELISA tests showed it is produced satisfactorily under these
conditions so it is most likely due to a problem in the folding of the PH binding domain.
This domain has been used successfully for this type of experiment in mammalian
cells216, and the fact fluorescence is detected implies the protein is being produced, so
the failure is most likely a problem with folding of the PH domain in the E. coli
cytoplasm.
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Cytoplasm (red)

Overlay

Figure 14. Localization of the GFP tagged PI4P binding OSBP-PH domain
Scale bar is 2 μm. The second row shows a zoom in on the bottom left of the top image
as indicated by the square. Note the lack of membrane localization in the green channel.
The line observed in the green channel (indicated with an arrow in the lower left panel)
is an error of the scanning system during the image acquisition.
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For the PIP2 binding test I used the PLCδ-PH domain, which binds PIP2. It is expected
that membrane localization of the probe will be observed only in the cells expressing all
3 enzymes required for PIP2 production and growing in LB media with inositol. Several
controls can be used for this system in order to make sure that if membrane localization
of the probe is observed it is due to the expected interaction. The first control uses the
same cells as the main experiment, expressing all 3 enzymes, but growing without
inositol. In this control no phosphoinositides should be produced and no halo should
form, confirming that the appearance of the halo is not due to some unexpected effect
of the enzymes being present. A second control uses a control system that has no
enzymes (in this case an empty plasmid) but grown with inositol in the media, showing
that inositol on its own also does not cause membrane localization of the probe. A final
control in which I mutated the binding site of the PLCδ-PH domain to eliminate its
possible interaction with PIP2 also showed no halo even when the enzymes necessary
and inositol were present, thus showing that the interaction depends specifically on its
binding to PIP2.

This mutation approach had not been attempted before so I used the structural
knowledge of the molecule published in the literature159 and performed 8 amino acid
changes to the residues that were implicated in PIP2 binding: K30A, K32A, W36A, R40A,
E54A, S55A, R56A, K57A (numbering follows that of Ferguson and coworkers159). A
representative image of each of these 3 controls and the experimental treatment is
presented in Figure 15. In some cells the levels of protein expression are high and it
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starts aggregating on the cell poles, in what might be the beginning of, or a fully formed,
inclusion body. In this case the red fluorescence is also excluded from this area. It is
important to highlight that this does not indicate any interaction with phosphoinositides
but simply a known effect of protein overexpression in E. coli and analysis should
exclude cell poles to avoid confounding the results. In these cases the cells still show
diffuse fluorescence in the cytoplasm so there is enough protein to evaluate its
localization satisfactorily regardless of a fraction of it being part of these aggregations.

As can be seen in Figure 15 a line scan perpendicular to the major axis, thereby avoiding
the poles of the cell, shows a clear difference between the test and the controls. The
cytoplasmic signal shows a symmetric mono-modal distribution while that of the
membrane bound GFP tagged PLCδ-PH domain shows 2 peaks with a central dip in the
signal.
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Figure 15. Localization of the GFP tagged PIP2 binding PLCδ-PH domain
Scale bar is 2 μm. Images were modified to leave only one cell in the field. Line scans
were 10 pixels wide and are indicated by the purple rectangle on the overlay image.
Data from line scans was standardized to show the same amplitude on all channels.
Note the aggregation of protein towards the pole in some cells, in a way that excludes
the cytoplasmic red marker.
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In order to gain better confidence about the data, and avoid a possible selection bias, I
created a bimodality index. To calculate this index I split the curves obtained with the
line scan into three regions, taking the central 0.5 microns as the center region and the
remainder to each site as the left or right side accordingly. Then the maximum of the
left and right sides is averaged and divided by the minimum in the center region. In this
way a curve that follows a normal or symmetric mono-modal distribution will give a
value very close to 1, since the maximum outside the center region is almost the same
as the minimum inside. In the case of a bimodal curve this value should be higher than 1
because the average of maximums in the outside regions should be higher than the
minimum in the center region where the curve dips.

Since misalignment of the center region would bias the analysis towards values higher
than one, I divide the value obtained for the curve corresponding to the green channel
by that of the red channel (control channel). In this way any artifact due to
misalignment of the center region boundaries will be corrected for, bringing the index
value back to 1 for mono-modal curves. Figure 16 illustrates the index calculations. To
do the calculations I acquired 4 different fields for each treatment and scored 10 cells
per field picking them on the mCherry channel in order to avoid any bias when selecting
them. The only consideration when picking the cells was that they were separate
enough from other cells so a good curve could be obtained.
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Figure 16. Calculation of the bimodality index
The line scan for each channel is standardized to its maximum so both channels have
the same range. The maximum of the values in the outside (left and right) regions is
averaged and divided by the minimum in the center region. This value should be very
close to 1 for mono-modal distributions and higher than one for bimodal distributions.
In order to correct for the effect of misalignment of the center region boundaries, which
would lead to values higher than one, the green channel value is divided by the red
(dashed) channel value. In this way any misalignment is corrected for, bringing the value
back to one for mono-modal distributions. Theoretically this correction would not be
necessary if the alignment was perfect but, as can be seen on the right side of the red
(dashed) channel in the figure, small variations in the data make the alignment
imperfect and the correction is appropriate.
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The results obtained with the bimodality index are presented in Figure 17. The data
confirms the localization of the PIP2 binding PH domain to the membrane only when
PIP2 is present and in a manner directly dependent of PIP2 binding by the PH domain.
While this could be observed from the images, being able to do a quantitative test
allows for more certainty in the assessment, and confirms in a completely independent
way the success of the system I developed in producing phosphoinositides.
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Figure 17. Bimodality index measures for the PIP2 binding PH domain
Each treatment had a sample size of 40 cells that came from 4 different fields, each with
10 cells measured. Graph shows the mean bimodality index and the standard deviation
of the sample. All controls show an index value close to 1 as expected for mono-modal
curves. There is a statistically significant difference between the localization test and all
controls as assessed by a one-way ANOVA analysis and a post hoc Tukey HSD test, both
with p<0.01 as indicated by **.
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3.2.

An application for the system

In order to illustrate how my system can be useful I decided to build a test for the
current model of non-conventional protein export for human basic fibroblast growth
factor (FGF2). FGF2 is a classic example of protein export in a manner independent of
the Golgi and endoplasmic reticulum. While several transporters have been proposed to
be involved in other models of non-conventional protein export, there is no evidence of
their involvement in FGF2 export223. The current model proposes that FGF2 is translated
and released into the cytoplasm, after which it becomes phosphorylated at tyrosine 82
by Tec-kinase. It is not clear if this phosphorylation occurs in the cytoplasm or at the
plasma membrane but it is more likely it occurs at the plasma membrane given that is
the normal Tec-kinase localization224. This phosphorylation enhances FGF2
oligomerization after binding to PIP2 for which it has a KD of approximately 1 μM225.
PIP2 binding drives membrane localization and together with the phosphorylation at
tyrosine 82 induces oligomerization of FGF2226. While the lack of this phosphorylation
diminishes export of FGF2 it does not entirely abolish it 227, suggesting that the system is
perhaps more robust than expected. A schematic of the current model is presented on
Figure 18.
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Figure 18. Schematic representation of the current FGF2 export model
FGF2 is synthesized and released to the cytoplasm, it is then phosphorylated in tyrosine
82 by Tec-kinase, this phosphorylation enhances binding to PIP2 and oligomerization
forming a temporary channel that allows it to reach the outside of the cell. Once in the
outside of the cell it releases PIP2 and binds to heparan sulfate proteoglycans. The
binding site for PIP2 is shared with that of heparan sulfate proteoglycans, but the
affinity is higher for the later creating a ratchet for accumulation of FGF2 in the outside
of the cell.
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After oligomerization of FGF2 is it believed that a membrane pore is produced which
allows FGF2 to cross through the plasma membrane reaching the extracellular space.
This pore allows the diffusion of small molecules, and its hypothesized to be lined with
PIP2, although this has only been shown to be the case in vitro 227. It has been shown
that FGF2 exports in a fully folded conformation and in fact that the folded state is
required for its export228. Once at the extracellular side FGF2 binds to heparan sulfate
proteoglycans which act as an anchor. The binding site is partly shared between PIP2
and heparan sulfate proteoglycans226 but the affinity for heparan sulfate proteoglycans
is significantly higher than for PIP2 with a KD of approximately 10 nM229. This anchoring
mechanism generates the directionality of the FGF2 movement without the need for
energy consumption in the process230. Two surface cysteines have recently been shown
to be important for the oligomerization of FGF2 at the pore in a manner that seems to
be independent of any accessory proteins, but it is hypothesized that they function
directly at the pore since the reducing environment at the cytoplasm would not allow
disulfide bridge formation 231.

This model represents a problem on which to try my system because it is otherwise
impossible to confirm the sufficiency of the proposed components in-vivo. At the same
time there is extensive evidence supporting each step of the process in the model, thus
an in-vivo, independent test for the sufficiency of the proposed components would
provide very strong support for the model. Additionally, there are several experimental
advantages to testing this model. FGF2 export isn’t impaired when it is fused to a
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protein tag, such as GFP, and a phosphomimic using glutamate substitution for tyrosine
82 (Y82E) completely restored FGF2 export when Tec-kinase activity was experimentally
ablated224. The binding site for PIP2 can also be eliminated by using 3 point mutations
K127Q,R128Q, K133Q226. These findings allow me to create a very clear test for the
sufficiency of the components since a negative control can be stablished by abolishing
PIP2 binding, and the wild type and phosphomimic FGF2 molecules can also be
evaluated. Since in some instances it has been shown that a double phosphomimic
(replacing the aminoacid that is phosphorylated by two glutamates instead of one)
resembles better the behavior of a phosphorylated protein 232, 233 I also included a
double phosphomimic, Y82EE, construct for my tests.

Since E. coli is a gram negative, if FGF2 expressed in this bacterium were to export
successfully it would be trapped between the plasma membrane and the outer
membrane in the periplasmic space. However, given that my system does not have
heparan sulfate proteoglycans to drive the export of FGF2, under the current model
FGF2 would only form pores and remain attached to the plasma membrane. It is unclear
if in this state FGF2 will face the outside of the plasma membrane, the inside, or
oscillate between the two states. The fact that the binding site is shared between PIP2
and heparan sulfate proteoglycans indicates that FGF2 will have to release PIP2 and be
exposed to the extracellular space at least some of the time.
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Because of this ambiguity I chose a system that would inform on FGF2 forming a pore
regardless of FGF2 separation from the membrane or the direction it faces if attached to
it. For this I used the NanoLuc Luciferase assay. This consists of a luciferase enzyme
optimized to reduce its size (about 19 kDa) to which I will refer as NanoLuciferase, and
an optimized substrate. Upon encountering the substrate NanoLuciferase catalyzes its
degradation releasing photons. One important advantage over other luminescent
systems is that this reaction does not require ATP as a cofactor, with all energy required
stored in the chemical structure of the substrate. This substrate is not membrane
permeable so if added to the media it will only be available on the periplasm of an intact
E. coli, with only a basal amount reaching the cytoplasm. NanoLuciferase can be
expressed as a C terminal fusion protein with FGF2, and this fusion should not interfere
with export since FGF2 has been shown to export successfully with a GFP fused to its Cterminus, and GFP is a larger protein (27 kDa).

Using this reporter assay it’s possible to evaluate the effect of PIP2 on the formation of
the membrane pore by FGF2 whether it remains attached to the plasma membrane or
released to the periplasm. If FGF2 forms a pore in my system a luminescent signal can
be produced in 3 different ways. If FGF2-NanoLuc is released to the periplasm, a signal
should be observed since the NanoLuciferase will have access to the substrate added to
the media; this would also be the same if FGF2-NanoLuc remains attached to the plasma
membrane but facing the periplasm. Finally, in the case that only the pore is formed, but
FGF2-NanoLuc is neither released to the periplasm not facing it, some level of substrate
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should be able to diffuse through the pore and be accessible to FGF2-NanoLuc in the
cytoplasm or inner side of the plasma membrane, producing a signal. An additional
advantage of this reporter is that it allows for standardization of the results to the
overall level of expression of the fusion protein. A percentage of luminescence can be
obtained by measuring the luminescence before lysis (signal of the treatment), and after
lysis of the cells (maximum signal possible, a measure directly proportional to the level
of protein expression), correcting for differences in the expression levels of the different
constructs being compared.

For these tests I used a plasmid with a ClodF13 origin of replication and an ampicillin
resistance marker. In this way the plasmid is fully compatible with my system for PIP2
production. I expressed the FGF2-NanoLuc reporter constitutively to avoid problems
with variable induction of the protein between constructs. For this I used the same
constitutive promoter I used for expression of the enzymes required for PIP2
production. This FGF2-NanoLuc construct constitutes my wild type reporter (FGF2NanoLuc-wt), and on it I performed site directed mutagenesis to obtain three more
constructs: FGF2-NanoLuc unable to bind to PIP2 by including the mutations K127Q,
R128Q, K133Q (FGF2-NanoLuc-NoBinding), FGF2-NanoLuc phosphomimic (FGF2NanoLuc-Y82E), and FGF2-NanoLuc double phosphomimic (FGF2-NanoLuc-Y82EE).

Each of the four constructs is expected to behave differently reflecting its proposed fit
with the model of FGF2 export. FGF2-NanoLuc-NoBinding should show the lowest signal,
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since it is unable to bind to PIP2 and therefore should not be able to form pores; this will
be the background signal for the system. FGF2-NanoLuc-wt should show the same low
level of signal or perhaps a little higher since it should bind to PIP2 but it lacks the
phosphorylation that has been shown to be important for enhancing its oligomerization
and pore formation. Finally, FGF2-NanoLuc-Y82E and FGF2-NanoLuc-Y82EE should both
present the highest level of signal since they have a phosphomimic mutation, allowing
them to oligomerize successfully, forming the pore. It is possible that the double
phosphomimic behaves differently, since in theory it is a better substitute for the
natural phosphorylation, but it might also not work as well since the backbone of the
protein is altered by extending its length.

Using my system to test these four FGF2-NanoLuc constructs allows testing the effect of
PIP2 on the pore forming behavior of FGF2 by using two types of cells for each
construct: control and test cells. Control cells do not have the enzymes required for
phosphoinositide synthesis, allowing to test the effect of inositol on its own. This is
important to make sure that inositol has no effect on the system on its own,
confounding the results. The test cells on the other hand express the enzymes required
for PIP2 synthesis, and differences observed when inositol is added are due to the
production of PIP2. The test can be easily performed and measured on a plate reader
where the initial OD600 of the culture as well as its luminescence is measured, and then
each well is measured again after lysis of the cells. Results of the experiment are
presented on Figure 19.
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Figure 19. FGF2 export tests with 2 mM inositol
Cells were grown in LB media supplemented with the appropriate amount of inositol for
3h before an initial luminescence measure in a plate reader. After this measure the cells
were lysed and the total luminescence was measured. The control treatment lacks the
enzymes required for PIP2 production. Data shown is the average of 4 replicates and the
distribution is the standard deviation of the samples. A two way ANOVA test found both
the constructs, the treatment (PIP2 vs control), and the interaction to have a significant
effect on the signal with p<0.01. A post hoc Tukey HSD test determined that FGF2NanoLuc-NoBinding is significantly lower than the other constructs in the PIP2
treatment with p<0.01 as indicated by **.
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As can be seen in Figure 19, all constructs showed little difference between the
treatment of inositol and no inositol in the control system, which lacks the enzymes to
synthesize PIP2. This is a basic control and this is the expected result confirming that
inositol on its own has no effect on FGF2 export. While the effect sizes observed in the
PIP2 treatment are not very large, varying between 6 and 10 % of the total
luminescence, they are significant as determined by the two way ANOVA test. This is
important because the value observed is too high to be due to the small fraction of cells
that might die randomly during the experiments; thus the differences observed are in
fact due to the different factors being evaluated (effect of PIP2 and different variants of
FGF2). Unexpectedly PIP2 had an effect on all constructs, with an increase in the
percentage of signal before lysis observed even for FGF2-NanoLuc-NoBinding when
inositol is added to the media. This effect is dependent on PIP2 directly, as it was not
observed in the control cells (which do not express the enzymes required for PIP2
synthesis). This suggests that even with the mutations to its binding site FGF2-NanoLucNoBinding is able to form a pore in a manner dependent on PIP2. Since its binding site is
impaired or possibly entirely non-functional this might be an effect of PIP2 on
membrane properties instead of on its oligomerization. This is consistent with the
importance of PIP2 at the membrane for the pore formation, where its shape would
allow for the curvature deformation required for a hypothesized toroidal pore 227. All
other constructs (wild type and both phosphomimics) showed a statistically significant
higher signal which confirms the observation that the binding for PIP2 enhances pore
formation. On the other hand the fact that the phosphomimics do not perform
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significantly better than the wild type construct suggest that this phosphorylation is not
as important as postulated although it shows slightly reduced signal compared to them.

In order to gain more insight into the process I repeated the test adding 5mM instead of
2mM of inositol into the media. While the concentration tests effects on PIP2
production in my system showed the production saturated around 2mM of inositol, if
this saturation is the product of feedback on the enzymes the sequestration of PIP2 by
FGF2 would induce the production of more PIP2. The increased inositol could also vary
the dynamics of production even if the overall maximum level remains the same,
reaching the maximum concentration of PIP2 faster. This would allow for more of the
FGF2 to form pores during the growth time of the cells, which I kept constant at 3 hours
to guarantee the measures are performed during the exponential growth phase of the
cells. In this way if the inositol concentration required for pore formation is reached
earlier, there is more time for pore accumulation. Additionally I added a new control, in
which I replaced the FGF2 in the reporter for mCherry. Since mCherry does not interact
with PIP2 in any way this mCherry-NanoLuc construct can determine whether the signal
observed in the other treatments is in fact due to the interaction between FGF2 and
PIP2 or somehow a passive result perhaps altering the permeability of the membrane to
the NanoLuciferase substrate. Results of this experiment are presented in Figure 20.
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Figure 20. FGF2 export tests with 5 mM inositol
Cells were grown in LB media supplemented with the appropriate amount of inositol for
3h before an initial luminescence measure in a plate reader. After this measure the cells
were lysed and the total luminescence was measured. The control treatment lacks the
enzymes required for PIP2 production. Data shown is the average of 4 replicates and the
distribution is the standard deviation of the samples. A two way ANOVA test found both
the constructs, the treatment (PIP2 vs control), and the interaction to have a significant
effect on the signal with p<0.01. A post hoc Tukey HSD test determined that FGF2NanoLuc-NoBinding is not significantly different from FGF2-NanoLuc-wt and that these
are significantly lower than both phosphomimics which are also significantly different
between themselves. All these differences were significant with p<0.01 as indicated by
**. The very small value obtained for the mCherry construct is indicated on the graph
since the scale does not allow visualizing it.
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In the new 5mM inositol experiment, the control system, which does not produce PIP2,
showed the same lack of effect as in the previous 2mM treatment for all constructs. This
confirmed the previous observation of inositol not having an effect on its own. The
mCherry control (which was performed only for the system producing PIP2) showed no
difference between the inositol and no inositol treatment, confirming that neither
inositol not PIP2 alter the background level of signal of NanoLuciferase in the E. coli cells
used for my studies. Just as in the 2mM inositol treatment, FGF2-NanoLuc-NoBinding
showed a significant increase in signal upon inositol addition and in this case the effect
size is much higher, increasing from about 6% in the 2mM inositol treatment to about
22% in the 5mM inositol treatment. The implication is the same as in the previous
experiment, showing that PIP2 has an effect on FGF2 pore formation (and possibly
export) that does not depend fully on the described binding site. In this case the signal
in FGF2-NanoLuc-wt wasn’t significantly different from FGF2-NanoLuc-NoBinding and
these were both significantly lower that the signal of the phosphomimics. The double
phosphomimic (FGF2-NanoLuc-Y82EE) showed lower signal than the single
phosphomimic (FGF2-NanoLuc-Y82E) but the overall patterns are the same. The double
phosphomimic is therefore not an improvement over the single phosphomimic and does
not add any new information to the tests.

The lack of a difference between the wild type construct and the non-binding mutant
might reflect a saturation effect. Based on the combined data of the 2mM and 5mM
inositol tests I propose that a shift in the dominant limiting factor for export is occurring.
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At both concentrations the phosphomimic, which can both bind to PIP2 and oligomerize
successfully, exports better than the other constructs. At the same time the non-binding
mutant, which has impaired PIP2 binding and lacks the phosphorylation therefore
showing impaired oligomerization, presents the lowest level of export at both
concentrations. The wild type on the other hand should bind to PIP2 successfully but
lacking the phosphorylation should have impaired oligomerization, and at lower
concentrations (2mM inositol) is able to export at a rate similar to that of the
phosphomimic. This implies that in this situation PIP2 might be limiting the system, thus
differences in oligomerization are not that important. Once PIP2 is increased (at 5mM
inositol) the limiting factor is not binding to PIP2 but oligomerization of the FGF2
molecule. The impaired binding to PIP2 has little effect given an excess of PIP2 in the
membrane and the oligomerization, which is dependent on the phosphorylation,
becomes the dominant factor limiting the pore formation and export of the molecule.

An important factor to consider is that this binding site of the PIP2 binding mutant
(FGF2-NanoLuc-NoBinding) might not be fully impaired. When the mutations to the
binding site were described a small fraction of mutant FGF2, less than 1%, would still
associate with plasma membrane like liposomes containing PIP2, although surface
localization would only be reduced to 20-30% of that of the control when only 2
mutations were present (K127Q,R128Q but not K133Q)226. In that same work it was
shown that the K133Q mutation impaired PIP2 binding, but more importantly heparan
sulfate proteoglycan binding, and this was the decisive factor to virtually eliminate all
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export of FGF2. While all mutations affect PIP2 binding and my system has all 3
mutations, the lack of heparan sulfate proteoglycan means that the mechanism of
action has to be different. The results observed in my system suggest that FGF2 pore
formation is enhanced by PIP2 regardless of the mutations. These results also support
the idea that at 5mM inositol PIP2 is in excess, rendering the mutation less relevant and
shifting the limiting factor to the oligomerization of the molecule.

While discussing these tests I have analyzed the difference between the no inositol and
inositol treatments, but it is also important to consider the absolute values of
background observed for them. These are shown for both experiments in Figure 21. The
important result in this case is the fact that the FGF2 constructs are able to produce a
signal corresponding to a range between 40% and 60% of the total signal. This is the
equivalent of saying that 40-60% of the protein produced encounters the
NanoLuciferase substrate. While the controls show that this is not dependent on
addition of exogenous inositol, and the PIP2 treatment clearly has an effect that
depends on the construct (this has been discussed already referring to figures 12 and
13), this very high background implies that FGF2 on its own, regardless of the presence
of inositol and/or PIP2, produces a very significant signal. While this is simply the
background level for the experiment, and as such one would just use it as a baseline,
there is important information reflected in this observation. For instance, the mCherry
control shows a background signal level of less than 1%, matching to the expected
cytoplasmic localization of the construct. This is not an artifact of protein production
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since the mCherry control produces significantly higher protein levels measured as the
total luminescence per OD600 unit (p<0.01 on a t test).

The very large background level observed for all FGF2 constructs means that a very large
fraction of the FGF2-NanoLuc constructs is able to reach, or be exposed to, the
periplasm even under control conditions. The mCherry control on the other hand shows
almost no signal. This is important because it shows unambiguously that inositol, PIP2,
and the enzymes required to synthesize it are not responsible for this signal thus it is an
effect of FGF2. An alternative to FGF2 being fully exported could be that a number of
pores are being formed on the membrane by the FGF2 constructs allowing the entrance
of a significant amount of NanoLuciferase substrate to the cytoplasm. I argue that the
magnitude of the effect indicates that FGF2 molecules are either being released to the
periplasm or on the outer leaflet of the plasma membrane but only going through a
pore state as a short lived intermediate, since having such a high amount of permanent
pores on the membrane would lead to major growth defects which I did not observe.
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Figure 21. Raw data for the FGF2-NanoLuciferase export tests
Cells were grown in LB media supplemented with the appropriate amount of inositol for
3h before an initial luminescence measure in a plate reader. After this measure the cells
were lysed and the total luminescence was measured. The control treatment lacks the
enzymes required for PIP2 production. The very small value obtained for the mCherry
constructs is indicated on the graph since the scale does not allow visualizing them.
Note that the mCherry construct was only evaluated in the presence of the PIP2 system
at 0 mM and 5 mM inositol in the media.
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FGF2 has been shown to not bind to phosphatidylethanolamine or PI, but to have
affinity for any phosphorylated phosphoinositide and for phosphatidylserine although at
a lower level than for phosphoinositides226. This indicates that it has a strong preference
for phospholipids with negatively charged head-groups, thus in the absence of PI4P and
PIP2 it should have low affinity for the plasma membrane of E. coli, which is composed
of phosphatidylethanolamine, phosphatidyl glycerol and cardiolipins (the latter two
having neutral head-groups). The fact that it is able to bind and export even in the
absence of PIP2 suggest that some hydrophobic interactions with the lipid tails and not
just the head-groups might be important for its export. Alternatively, it is possible that
phosphatidylserine, which is an intermediate for phosphatidylethanolamine production
in E. coli, is binding to FGF2 and this interaction allows FGF2 to anchor itself to the
membrane and initiate export. However, this is unlikely since phosphatidylserine can
only be detected in trace amounts in normally growing E. coli201 and will only
accumulate if phosphatidylethanolamine production is impaired, a situation that has
significant effects on the bacterium leading to lethality in the extreme cases204.

FGF2 might also be able to insert at membranes at a low rate even when PIP2 binding
and oligomerization are impaired. It is possible that this hypothesized insertion and
oligomerization is enough to cross the thinner plasma membrane found in bacteria
(which have phospholipids with shorter lipid tails) a fraction of the time but not enough
to allow for its export of the mammalian cell. Since my assays are end point assays the
observed result could reflect accumulation over the time of the experiment of FGF2 that
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exports at a low constant level. At this point this is a purely speculative mechanism and
elucidating it would require a variety of independent tests that are beyond the point of
this work, which is to demonstrate an application of my system.

Overall my experiments on FGF2 export support two main aspects of the current model;
they show that PIP2 enhances export of FGF2 and that the phosphorylation at Y82 also
enhances the export of the molecule. My data also shows that export of FGF2 is more
robust than expected, and that the effect of PIP2 is not only dependent on the reported
binding site, and/or that the binding site is not fully impaired by the mutations that have
been described in the literature.
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4. Conclusion and outlook

In this work I have built a new platform for the study of phosphoinositides in-vivo using
the bacterium E. coli, and have shown that the phosphoinositide production can be
controlled with the addition of inositol to the media allowing for very detailed
experimental manipulations. I have confirmed the production of PIP2 in my system with
both a biochemical characterization and an imaging approach, providing fully
independent observations as evidence that my system behaves as desired.

I have also applied my system to the study of FGF2 export from cells, confirming the role
of PIP2 and a phosphorylation of its tyrosine residue at position 82 in enhancing its
export. Additionally I have found some puzzling results suggesting that FGF2 export is
more robust than expected in bacteria. This results needs to be confirmed and explored
with alternative approaches to provide independent evidence, and this is beyond the
scope of my project.

Overall the system I have developed shows the potential I set up to accomplish, and
provides a new tool for experimenters interested in phosphoinositide biology.
Opportunities are only limited by the boundaries imposed by E. coli in terms of protein
production. The adoption of the tool by other researchers will be the ultimate indication
of its value.
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5. Appendix
5.1. Supplementary Protocol: Lipid extraction protocol

This Extraction Protocol is adapted from the Bligh & Dyer protocol. The volumes
reported here are for a 10 mL pellet but can be adjusted to other sizes with a linear
approximation. The protocol assumed an 80 μl pellet came out of the 10 ml of culture,
but this measure does not need to be precise.

-Take 10 ml of culture at OD600 equal to 1 and pellet gently (1-3 min at 8000 rcf)
-Entirely remove the supernatant and store the pellet at -80C until fully frozen. The
pellet can be stored like this until the lipid extraction is to be performed
-Add 420 μl of water to the frozen pellet ant thaw while resuspending with pipet mixing.
Make sure the pellet is fully resuspended before continuing
-Add 1250 μl of methanol
-Add 625μl of chloroform
-Vortex until fully mixed, no cell clumps should be visible
-Add another 625μl of chloroform
-Vortex until fully mixed, no cell clumps should be visible
-Add 600 μl of ddH20
-Vortex until fully mixed, at this point two phases become obvious and start appearing
even without centrifugation
-For total lipid extraction add 25 µl of HCl
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-Vortex until fully mixed, the two phases are equally evident here
-Centrifuge at 100-150 rcf for 5 minutes
-Take the bottom phase of this solution, this is the organic phase and contains the lipids.
The upper phase contains proteins and other water soluble molecules. Avoid pipetting
up any of the top phase by pipetting a bit of air into the pipette and releasing it while
moving through to the aqueous top phase. Between the two phases there is normally a
layer of white material, mostly protein that is to be avoided
-Dry the bottom phase with argon until there is no solution remaining. These are the dry
lipids. This should be done on glass vials
-Resuspend the mix on 100 µl of chloroform:methanol mix 20:9. I the resuspension
turns problematic this can be sonicated in ice cold water to help, or a higher volume of
chloroform:methanol can be used

Protocol variations:

For a cleaner extraction the obtained bottom phase can be washed with authentic
upper phase. The authentic upper phase is obtained from the same protocol but in a
tube in which instead of a sample pellet 80 µl of water were used. This cleaning step can
be repeated if desired but for most extractions no cleaning is required.
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For separation of charged lipids the bottom phase can be obtained before the addition
of HCl, saving the upper phase and layer of white material. The bottom phase so
obtained is enriched in the uncharged phospholipids. Then the charged lipids can be
obtained by adding new authentic bottom phase to the remaining top phase and white
material and only then adding the HCl to acidify the mixture. The new bottom phase
obtained will be enriched on the charged phospholipids, in this case PI4P and PIP2.

5.2. Supplementary discussion: Thin layer chromatography for phosphoinositide
detection

Besides the detection by mass spectrometry mentioned in the main text a common
technique for the detection of phosphoinositides consists on the chromatographic
separation of the extracted phospholipids. This method is known as thin layer
chromatography (TLC). In TLC differences in the affinity of each lipid for the moving
phase relative to their affinity for the solid face create a separation of distinct lipid
classes allowing for their detection. The detection can be done in a nonspecific manner,
for example using iodine vapor, or in some cases with chemical reactions specific to the
head-group of the phospholipid of interest, but to the best of my knowledge there is no
specific chemical method for the detection of phosphoinositides on TLCs. For this reason
it is common to use radioactively labelled inositol; this allows to make a direct measure
of the phosphoinositides present in the sample, integrating over the spread of each
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class. The method is highly sensitive and there is virtually no interference of other
phospholipids since only phosphoinositides will contain the radioactive molecule.

For this project the use of radioactivity was undesirable since it would add a significant
cost and regulatory burden, thus I tested the use of non-specific iodine detection.
Measuring spots on the solid silica phase I could detect amounts as small as 0.1 μg of
PIP2 (Supplementary Figure 1), which was a satisfactory observation. However once in a
complex mixture that same level of sensitivity was problematic because the noise left by
other classes of phospholipids during the run made it very hard to detect small amounts
of control phosphoinositides, with the effective detection limit in the range of 50 μg
(Supplementary Figure 2). This occurred because the distribution of any particular
phospholipid had long tails, thus the signal of the very small amounts of
phosphoinositide was diluted among the tails of the very abundant E. coli phospholipids.
Given the measured sensitivity in my system, successful detection of the
phosphorylated phosphoinositides would require them to be produced in the range of
5% of total phospholipids, which is too high relative to their abundance in eukaryotic
cells. In my case the phosphorylated phosphoinositides are produced at very small
amounts, a fraction of less than 0.5% of the phospholipids in the bacterium. It is thus
clear that TLC would only be useful for my project if combined with radioactive labeling
of the inositol added to the media.
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Supplementary Figure 1. Sensitivity and effective TLC sensitivity of iodine vapor
detection of phospholipids:
A) PIP2 was spotted at different amounts on a Silica Gel Hard Layer plate, and this was
developed with iodine crystals in a closed box until signal was detected (approx. 15
min), after which the plate was scanned. Note that no solvent was used for this test.
B) A combination of 375 μg of E coli total phospholipids and varying amounts of PI4P
were spotted at the bottom of the plate for each lane, plus a control lane where PI4P
was spotted alone. After the run of the solvent to the top of the plate, the plate was
allowed to air dry and developed with iodine crystals in a closed box until signal was
detected (approx. 15 min), after which the plate was scanned.
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An additional problem with the use of TLC is that it cannot differentiate among the
different kinds of mono-phosphorylated or di-phosphorylated phosphoinositides since
each category will run in the same manner regardless of which of the positions in the
inositol ring is phosphorylated. While in my case this shouldn’t be a problem, since I only
have PI4P as a mono-phosphorylated phosphoinositide and PIP2 as a di-phosphorylated
one, this is an important consideration for other projects.

For all TLC test mentioned I used plates with a Silica Gel Hard Layer (HL) 250 µm, using a
mixture of chloroform-methanol-acetic acid-water-formic acid (35:15:6:2:0.3) as the
solvent. After running to completion plates were allowed to air-dry, once dry the plated
were incubated with iodine crystals in a closed box until signal was observed
(approximately 15 minutes). The plates were then scanned using a conventional
document scanner.

5.3. Supplementary discussion: Alternative reporters for FGF2 export detection
As mentioned in the main text, the use of the NanoLuc reporter allowed a precise
measure of FGF2 export that is corrected for differences in protein expression. This is an
important factor to consider when doing this type of analysis because the expected
response of the system is small, thus small variation in the protein expression among
constructs might mask the signal of interest. It is important to recall here that the
difference between treatments and control at 2mM inositol in the media is only
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between 6 and 10% of the signal. While several alternative approaches could have been
used since they have the potential to detect periplasmic localization of FGF2, most of
them have caveats that make them less appropriate than the NanoLuc assay employed.

As a basic approach, biochemical enrichment for periplasmic protein could have been
employed. This approach has several problems, the main one being the fact that, as
enrichment, it is very prone to some level of leakage of cytoplasmic proteins into the
enriched periplasmic fraction. While this is a minor problem for proteins that should
mostly be in the periplasm, in my system I expect a small signal and a very significant
cytoplasmic contribution, thus the small level of contamination with cytoplasmic
proteins expected can easily mask the signal. The second problem is the variability of
the level of cytoplasmic contamination among samples; again this could easily mask a
low level of signal. A final problem consist on the quantitation of the protein in the
isolated fractions, since it would require a quantitative western blot, which is not a
strength of the western blot technique, or a mass spectrometric approach, which would
require the development of several time consuming controls. As a test for this approach
I performed periplasmic protein enrichment on bacteria expressing cytoplasmic GFP, in
theory the periplasmic fraction should be entirely free of GFP, in practice it is expected
that it had a small amount would be present. On a western blot I detected a strong GFP
band in the periplasmic fraction, confirming that this approach would not be useful for
my FGF2 tests where only small differences were expected.
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A second approach could consist on the immune detection of the localization of FGF2.
This could be done both with immunohistochemistry and with electron microscopy. I did
not attempt either of these approaches for two reasons. First the test would be done in
fixed permeabilized cells, thus once the size of the antibodies used is taken into account
it would be complex to determine whether the molecules detected are truly in the
periplasm or simply associated with the plasma membrane but on the cytoplasm. This
problem would favor the use of electron microscopy over that of regular
immunohistochemistry since the resolution of the latter would not be satisfactory for
this test. The second problem with this approach is purely logistic, because even if the
resolution obtained is satisfactory, it would require a significantly larger amount of time
to perform the analysis and obtain enough sample size to perform statistical tests.
Differences in the efficiency of labeling among samples could also be a big problem,
again masking the small levels of signal expected.

Finally, the use of fluorescent proteins would be another valid alternative. Direct
measure of the localization of FGF2 could be an alternative, but there are several
problems with this approach. The main difficulty would consist in determining the
difference between periplasmic localization and localization to the inner side of the
plasma membrane. The very small size of the bacterium makes this distinction a very
hard problem to solve with conventional fluorescent proteins. This could be
circumvented using a pH sensitive fluorescent protein, since the pH of the media can be
controlled carefully in a flow chamber. The pH sensitive reporters in the cytoplasm
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should vary less upon media pH changes than those in the periplasm, given that the pH
in the cytoplasm is buffered by the bacterium. There are several pH sensitive fluorescent
proteins that could be used for this purpose. However results obtained with this analysis
depend directly on the fluorescent intensity (since it is the factor to vary with pH), and
fluorescent intensity depends on the levels of protein expression. Thus here again small
variations in protein expression among constructs could mask the small effects
expected. There is a special kind of pH sensitive GFP, known as ratiometric GFP, which
does not suffer from this caveat. This ratiometric GFP presents a shift of its absorbance
spectrum with pH, thus, instead of simply observing a decrease in brightness upon pH
change as in regular pH sensitive fluorescent proteins, a pH change creates a decrease in
fluorescence intensity when excited at one wavelength (405 nm), but an increase when
excited at another (475). This is a very useful property because instead of analyzing the
absolute intensity, one can take the ratio of fluorescence at both wavelengths (signal at
405nm/signal at 475 nm). This not only eliminates the problems of differences due to
varying amounts of protein between different constructs, but also slightly amplifies the
signal making its detection easier.

Compared to the NanoLuc approach the ratiometric pH sensitive GFP has the advantage
of allowing single cell analyses, but the disadvantage of being more labor intensive and
costly (due to the special microfluidic plates required for the control of the pH in the
media) thus reducing the amount of tests possible. The single cell measures do not
represent a particularly relevant advantage in my system since there is no reason to
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expect significant cell to cell variation, nonetheless, if cell to cell variation is present this
would be the ideal test to detect it.

I attempted to use the ratiometric GFP reporter for my system but could not get a
positive control to work thus I decided to use the NanoLuc approach which was working
satisfactorily. The problem observed was that a cytoplasmic ratiometric GFP would
produce the same signal variation (change in the ratio of signal at 405nm/signal at 475
nm) upon pH changes as one that had a twin-arginine translocation pathway signal and
should have been localized exclusively to the periplasm (this signal leads to the export of
folded proteins to the periplasm). The expectation was that the reporter with the
periplasmic localization signal would show more variation than the cytoplasmic
reporter. I later detected this problem was due to the failure of the signal to drive
periplasmic localization, with the fluorescence being diffuse in the cytoplasm instead of
showing periplasmic localization. This reporter remains a viable alternative to detect
FGF2 export but it I did not pursue it further since the NanoLuc assay allows me to
perform test faster.
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